WO2024035782A1 - Aav-mediated intramuscular delivery of insulin - Google Patents
Aav-mediated intramuscular delivery of insulin Download PDFInfo
- Publication number
- WO2024035782A1 WO2024035782A1 PCT/US2023/029845 US2023029845W WO2024035782A1 WO 2024035782 A1 WO2024035782 A1 WO 2024035782A1 US 2023029845 W US2023029845 W US 2023029845W WO 2024035782 A1 WO2024035782 A1 WO 2024035782A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- aav
- cleavable
- muscle
- peptide
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 197
- 229940125396 insulin Drugs 0.000 title claims abstract description 145
- 102000004877 Insulin Human genes 0.000 title claims abstract description 101
- 108090001061 Insulin Proteins 0.000 title claims abstract description 101
- 238000007918 intramuscular administration Methods 0.000 title abstract description 7
- 238000012384 transportation and delivery Methods 0.000 title abstract description 6
- 230000001404 mediated effect Effects 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 65
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 42
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 42
- 239000002157 polynucleotide Substances 0.000 claims abstract description 42
- 239000013598 vector Substances 0.000 claims abstract description 33
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims abstract description 28
- 210000000663 muscle cell Anatomy 0.000 claims abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 47
- 210000003205 muscle Anatomy 0.000 claims description 41
- 239000002245 particle Substances 0.000 claims description 35
- 230000003612 virological effect Effects 0.000 claims description 32
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 210000000234 capsid Anatomy 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 23
- 239000013607 AAV vector Substances 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 21
- 238000013518 transcription Methods 0.000 claims description 17
- 230000035897 transcription Effects 0.000 claims description 17
- 101710118538 Protease Proteins 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 14
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 13
- 108090001126 Furin Proteins 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 10
- 230000010415 tropism Effects 0.000 claims description 10
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 9
- 238000003776 cleavage reaction Methods 0.000 claims description 9
- 230000007017 scission Effects 0.000 claims description 9
- 210000002027 skeletal muscle Anatomy 0.000 claims description 9
- 210000003412 trans-golgi network Anatomy 0.000 claims description 9
- 102100032378 Carboxypeptidase E Human genes 0.000 claims description 8
- 108010058255 Carboxypeptidase H Proteins 0.000 claims description 8
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 8
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 7
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 6
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 6
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 6
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 6
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 6
- 210000004165 myocardium Anatomy 0.000 claims description 6
- 210000002460 smooth muscle Anatomy 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 101710111216 Activated RNA polymerase II transcriptional coactivator p15 Proteins 0.000 claims description 3
- 101710163386 Adenosylcobalamin-dependent ribonucleoside-triphosphate reductase Proteins 0.000 claims description 3
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 claims description 3
- XUBLMYHWSFRACH-CYDGBPFRSA-N Arg-Asn-Gln-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XUBLMYHWSFRACH-CYDGBPFRSA-N 0.000 claims description 3
- 102100021521 BPI fold-containing family B member 2 Human genes 0.000 claims description 3
- 101000899082 Homo sapiens BPI fold-containing family B member 2 Proteins 0.000 claims description 3
- 101001098833 Homo sapiens Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 claims description 3
- 101000654452 Homo sapiens Protein transport protein Sec16B Proteins 0.000 claims description 3
- 101001051709 Homo sapiens Ribosomal protein S6 kinase-related protein Proteins 0.000 claims description 3
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims description 3
- 101710180721 Probable adenosylcobalamin-dependent ribonucleoside-triphosphate reductase Proteins 0.000 claims description 3
- 102000012210 Proprotein Convertase 5 Human genes 0.000 claims description 3
- 108010022052 Proprotein Convertase 5 Proteins 0.000 claims description 3
- 102100036371 Proprotein convertase subtilisin/kexin type 4 Human genes 0.000 claims description 3
- 101710180646 Proprotein convertase subtilisin/kexin type 4 Proteins 0.000 claims description 3
- 102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 claims description 3
- 102100031481 Protein transport protein Sec16B Human genes 0.000 claims description 3
- 102100024914 Ribosomal protein S6 kinase-related protein Human genes 0.000 claims description 3
- 108010068380 arginylarginine Proteins 0.000 claims description 3
- 102200072130 rs139340178 Human genes 0.000 claims description 3
- 108010093297 tetrapeptide carbamate Proteins 0.000 claims description 3
- 102100035233 Furin Human genes 0.000 claims 2
- 108010075254 C-Peptide Proteins 0.000 abstract description 12
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- 241000702421 Dependoparvovirus Species 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 27
- 239000000203 mixture Substances 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 18
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 12
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102000004961 Furin Human genes 0.000 description 10
- 239000003623 enhancer Substances 0.000 description 10
- 229910001629 magnesium chloride Inorganic materials 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 241000701022 Cytomegalovirus Species 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 229920001983 poloxamer Polymers 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 229960000502 poloxamer Drugs 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010044052 Desmin Proteins 0.000 description 5
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 5
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 5
- 108010076181 Proinsulin Proteins 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- 102100036912 Desmin Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 4
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 4
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000007997 Tricine buffer Substances 0.000 description 4
- 108010065729 Troponin I Proteins 0.000 description 4
- 210000005045 desmin Anatomy 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000002867 manganese chloride Nutrition 0.000 description 4
- 239000011565 manganese chloride Substances 0.000 description 4
- 229940099607 manganese chloride Drugs 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 210000003098 myoblast Anatomy 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920001993 poloxamer 188 Polymers 0.000 description 4
- 229940044519 poloxamer 188 Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108010066381 preproinsulin Proteins 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- -1 Poloxamer 184 Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000004739 secretory vesicle Anatomy 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002507 Poloxamer 124 Polymers 0.000 description 2
- 229920002508 Poloxamer 181 Polymers 0.000 description 2
- 229920002511 Poloxamer 237 Polymers 0.000 description 2
- 229920002516 Poloxamer 331 Polymers 0.000 description 2
- 229920002517 Poloxamer 338 Polymers 0.000 description 2
- 102000006437 Proprotein Convertases Human genes 0.000 description 2
- 108010044159 Proprotein Convertases Proteins 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000007994 TES buffer Substances 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 2
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 229960003390 magnesium sulfate Drugs 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940071125 manganese acetate Drugs 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000009179 medical nutrition therapy Methods 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229940093448 poloxamer 124 Drugs 0.000 description 2
- 229940085692 poloxamer 181 Drugs 0.000 description 2
- 229940116406 poloxamer 184 Drugs 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229940044476 poloxamer 407 Drugs 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 description 2
- 235000011151 potassium sulphates Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000013608 rAAV vector Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150115442 CKM gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000928044 Homo sapiens Desmin Proteins 0.000 description 1
- 101500025354 Homo sapiens Insulin B chain Proteins 0.000 description 1
- 101100456626 Homo sapiens MEF2A gene Proteins 0.000 description 1
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150072453 MEF1 gene Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100509781 Mus musculus Ckm gene Proteins 0.000 description 1
- 101100079042 Mus musculus Myef2 gene Proteins 0.000 description 1
- 102100031790 Myelin expression factor 2 Human genes 0.000 description 1
- 101710107751 Myelin expression factor 2 Proteins 0.000 description 1
- 102100021148 Myocyte-specific enhancer factor 2A Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 101710204040 Myosin-3 Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100032132 Neuroendocrine convertase 1 Human genes 0.000 description 1
- 102100037732 Neuroendocrine convertase 2 Human genes 0.000 description 1
- 101100150290 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) sre gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108090000545 Proprotein Convertase 2 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 101100010928 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) tuf gene Proteins 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101150001810 TEAD1 gene Proteins 0.000 description 1
- 101150074253 TEF1 gene Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000001196 cardiac muscle myoblast Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 101150014102 mef-2 gene Proteins 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- 101150042523 myod gene Proteins 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940103453 novolin Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- Eukaryotic secreted proteins are generally processed and secreted via either the constitutive pathway or the regulated pathway.
- Insulin is one of many secreted proteins in mammals. It is synthesized as an inactive preproinsulin having a signal peptide. The preproinsulin is translocated directly into the rough endoplasmic reticulum (RER), where its signal peptide is removed by signal peptidase to form proinsulin. As the proinsulin naturally folds, a C-terminal sequence called “A-chain” and an N-terminal sequence called “B-chain” become covalently linked together with three disulfide bonds (with one of the three being an intra-chain disulfide bond linking two Cys residues of the A-chain). This folded proinsulin then transits through the Golgi apparatus, and is packaged into specialized secretory vesicles.
- RER rough endoplasmic reticulum
- proinsulin is cleaved by specialized peptidases called proprotein convertase 1/3 and proprotein convertase 2, removing the middle part of the protein, called the “C-peptide.”
- carboxypeptidase E removes two pairs of amino acids from the protein’s ends, resulting in active insulin - the insulin A- and B- chains, connected with two disulfide bonds.
- One aspect of the invention provides an engineered insulin polypeptide (E-insulin) engineered from a wild-type insulin sequence in a mammal, comprising: (a) a first cleavable heterologous peptide, between the insulin B-chain and the insulin C-peptide of the wild-type insulin; and, (b) a second cleavable heterologous peptide, between the insulin C-peptide and the insulin A-chain of the wild-type insulin; wherein the first and the second cleavable heterologous peptides are both native sequences of the mammal.
- E-insulin engineered insulin polypeptide
- the mammal is a human.
- the first and the second cleavable heterologous peptides are both cleavable by a serine endoprotease expressed in muscle tissues.
- the serine endoprotease is a subtilisin-like endoprotease, such as furin, PACE4, PC4, PC5/6, or LPC/PC8.
- the first cleavable heterologous peptide and the second cleavable heterologous peptide independently comprise a sequence motif Arg-Xaa-Xaa-Arg (wherein Xaa is any amino acid) or Lys/Arg-Arg.
- the serine endoprotease is present or expressed in trans-Golgi network (TGN), such as TGN of muscle tissue / cell.
- TGN trans-Golgi network
- the serine endoprotease is Furin.
- the first cleavable heterologous peptide and the second cleavable heterologous peptide both comprise, consist essentially of, or consist of an amino acid sequence independently selected from RGVFRR (SEQ ID NO: 3); RAKR; RKKR; RKYR; RRKR RRRR; RQRR; LSRR; RKRR; RHKR; RERR; RPRR; RARR; RS AR; LRKR; RTRR REAR; RNTR; RLRR; RWRR; RGKR; RVKR; RHPR; RRGR; RVRR; RDRR; RTGR REAR; RFKR; RYKR; RHAR; RLLR; RVGR; RRAR; HPKR; RFPR; RRTR; RNQR; RSRR RRRK; RSIR; RTPR; RPAR; RNHR; RKTR; RKNR; RLKR; RNRR; RKSR; RMKR
- the insulin B-chain comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 2.
- the insulin C-peptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 4.
- the insulin A-chain comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 5.
- the E-insulin of the invention further comprises a signal peptide.
- the signal peptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1.
- the insulin A-chain and the insulin B-chain are covalently linked by a disulfide bond.
- the insulin A-chain and the insulin B-chain are covalently linked by two disulfide bonds.
- the E-insulin of the invention further comprises an H10D substitution on the insulin B-chain.
- Another aspect of the invention provides a mature E-insulin resulting from cleavage of the E-insulin of the invention described herein, at the first cleavable heterologous peptide and said second cleavable heterologous peptide, wherein said insulin A-chain and said insulin B-chain are covalently linked by two disulfide bonds.
- the mature E-insulin comprises a first remnant sequence of the first cleavable heterologous peptide, optionally, the first remnant sequence (and further optionally the last one or two basic residue(s) at the C-terminus of SEQ ID NO: 2) is removed by a carboxypeptidase (such as carboxypeptidase E) in said mature E-insulin.
- a carboxypeptidase such as carboxypeptidase E
- Another aspect of the invention provides a cleaved insulin C-peptide resulting from cleavage of the E-insulin of the invention at the first cleavable heterologous peptide and the second cleavable heterologous peptide, wherein the cleaved insulin C-peptide comprises a remnant sequence of the second cleavable heterologous peptide; optionally, the second remnant sequence (and further optionally the last one or two basic residue(s) at the C- terminus of SEQ ID NO: 4) is removed by a carboxypeptidase (such as carboxypeptidase E) in the cleaved insulin C-peptide.
- Another aspect of the invention provides a polynucleotide encoding the E-insulin of the invention described herein.
- Another aspect of the invention provides a vector comprising the polynucleotide of the invention described herein.
- the vector comprises a promoter operably linked to a transcription cassette comprising the polynucleotide of the invention.
- the promoter comprises: (1) a constitutively active eukaryotic promoter, (2) a muscle-specific promoter, and/or (3) a synthetic promoter.
- the vector comprises two promoters.
- the vector comprises: (1) a first transcription cassette comprising the polynucleotide of the invention operably linked to a first promoter (e.g., a muscle- specific promoter such as MCK, or a constitutive promoter such as CBA or CAG); and, (2) a second transcription cassette comprising the polynucleotide of the invention operably linked to a second promoter, such as a synthetic promoter; wherein the polynucleotides of the invention in the first and the second transcription cassettes are independently selected from the E-insulin of the invention described herein.
- a first promoter e.g., a muscle- specific promoter such as MCK, or a constitutive promoter such as CBA or CAG
- a second transcription cassette comprising the polynucleotide of the invention operably linked to a second promoter, such as a synthetic promoter
- the transcription cassette(s) further encodes a 5’-UTR region, a 3’-UTR region, and/or a polyA signal operably linked to the polynucleotide of the invention.
- the vector is an AAV (adeno-associated viral) vector further comprising a 5’ ITR and/or a 3’ ITR.
- AAV adeno-associated viral
- Another aspect of the invention provides an AAV viral particle comprising the AAV vector of the invention, encapsidated within a capsid.
- the capsid has a serotype with muscle tropism, such as tropism for skeletal muscle, smooth muscle, or cardiac muscle.
- the capsid has the serotype of AAV1, AAV2, AAV6, AAV7, AAV8, AAV9, AAV-DJ/8, AAV-RhlO, AAV-retro, AAV-PHP.B, AAV-PHP.eB, or AAV- PHP.S, or a genetically engineered AAV Capsid.
- Another aspect of the invention provides a method of delivering an engineered insulin polypeptide to a muscle cell, the method comprising contacting the muscle cell with the AAV viral particle of the invention.
- the muscle cell is in an animal, such as a human or a nonhuman mammal.
- the animal has Type 1 or Type 2 diabetes, or hyperglycemia.
- Another aspect of the invention provides a method of treating a subject in need of treatment for a disease treatable by insulin, the method comprising administering to the subject a therapeutically effective amount of the AAV viral particle of the invention.
- the AAV viral particle is delivered intramuscularly.
- the subject has Type 1 diabetes.
- the subject has Type 2 diabetes.
- the subject has hyperglycemia.
- FIG. 1 is a schematic (not to scale) illustration of the synthesis and processing of one embodiment of the engineered insulin (E-insulin) of the invention.
- FIG. 2 is a schematic (not to scale) illustration of a more detailed structure of the one embodiment of the E-insulin of the invention depicted in FIG. 1.
- FIG. 3 is a schematic (not to scale) illustration of a wild-type insulin structure for comparison with that of the E-insulin of FIG. 2.
- FIG. 4 is an electrophoresis image showing the plasmid constructs encoding with the full-length wild-type (FE) human insulin, or one E-insulin of the invention.
- the E-insulin insert after restriction enzyme digestion is slightly larger than that of the FL insulin.
- FIG. 5 shows that the processed mature insulin (E-insulin) were produced and secreted from mouse C2C12 muscle cells.
- FIG. 6 shows that the C-peptide was secreted and released from the E-insulin or FL insulin from mouse C2C12 muscle cells.
- FIG. 7 shows potency of secreted E-insulin in muscle cells by eliciting differentiation of C2C12 myoblast muscle cells into myotubes. Immunohistochemical localization of myosin heavy chain is used as molecular marker for myotube differentiation. The DAPI standing shows the locations of the muscle cell nuclei. DETAILED DESCRIPTION OF THE INVENTION
- the invention described herein provides an engineered insulin (E-insulin) construct and the E-insulin encoded thereby, wherein the E-insulin can be processed in vivo, in cells (such as muscle cells) that do not otherwise process wild-type preproinsulin to mature / active insulin.
- the invention is partly based on the introduction of two cleavable heterologous peptides that flanks the C-peptide in the E-insulin precursor, such that such cleavable heterologous peptides can be cleaved in the cells (e.g., muscle cells) to release mature insulin.
- E-insulin of the invention is that such cleavable heterologous peptides are both native sequences of the mammal. While not wishing to be bound by any particular theory, it is believed that the E-insulin with such cleavable heterologous peptides has reduced risk (if not without any risk) of causing host immune response, such as T- and B-cell mediated cellular and humoral immune responses against the E-insulin as both are native sequence of the mammal.
- an engineered insulin polypeptide (E- insulin) engineered from a wild-type insulin sequence in a mammal comprising: (a) a first cleavable heterologous peptide, between the insulin B-chain and the insulin C-peptide of the wild-type insulin; and, (b) a second cleavable heterologous peptide, between the insulin C- peptide and the insulin A-chain of the wild-type insulin; wherein the first and the second cleavable heterologous peptides are both native sequences of the mammal.
- “native sequences of the mammal” includes naturally existing sequences in the mammal. Such naturally existing sequences are unlikely to trigger undesirable host animal immune response, since such sequences are deemed self-antigens with respect to the host animal.
- the mammal is a human.
- the mammal is a non-human animal, such as a rodent (such as a mouse, a rat, a rabbit, a hamster, a guinea pig, etc), pets (e.g., all breeds of dogs and cats and pet mammals), a livestock mammal (such as a horse, a sheep, a goat, a pig, a cow / bull), or a non-human primate, such as a monkey (e.g., a cynomolgus monkey, a rehesus monkey etc).
- a rodent such as a mouse, a rat, a rabbit, a hamster, a guinea pig, etc
- pets e.g., all breeds of dogs and cats and pet mammals
- a livestock mammal such as a horse, a sheep, a goat, a pig, a cow / bull
- a non-human primate such
- the E-insulin is engineered from the wild-type (wt) insulin of the mammal.
- an E-insulin of the invention for human is based on / engineered from the wild-type human insulin sequence, and the cleavable heterologous peptides are also from human.
- heterologous peptides are “heterologous,” partly because these sequences / peptides do not originate from insulin or its precursor thereof.
- Any cleavable heterologous peptides may be used in the E-insulin of the invention, provided that they are cleavable by an enzyme expressed inside the target cell in which such E-insulin is to be expressed.
- the first and the second cleavable heterologous peptides are both cleavable by a serine endoprotease expressed in muscle tissues.
- the serine endoprotease is a subtilisin-like endoprotease, such as furin, PACE4, PC4, PC5/6, or LPC/PC8.
- the first cleavable heterologous peptide and the second cleavable heterologous peptide independently comprise a sequence motif Arg-Xaa-Xaa-Arg (wherein Xaa is any amino acid) or Lys/Arg-Arg.
- the serine endoprotease is present or expressed in trans-Golgi network (TGN), such as TGN of muscle tissue / cell.
- TGN trans-Golgi network
- the serine endoprotease is Furin.
- Furin is also known as PACE (Paired basic Amino acid Cleaving Enzyme). It is a member of family S8, and is a member of the subtilisin-like proprotein convertase family. The members of this family are proprotein convertases that process latent precursor proteins into their biologically active products. Furin is a calcium-dependent serine endoprotease that can efficiently cleave precursor proteins at their paired basic amino acid processing sites. The furin substrates and the locations of furin cleavage sites in protein sequences can be predicted by two bioinformatics methods: ProP (Duckert et al., Protein Engineering, Design & Selection 17 (1): 107-112, 2004) and PiTou (Tian et al., Scientific Reports. 2: 261, 2012), both incorporated herein by reference.
- ProP Duckert et al., Protein Engineering, Design & Selection 17 (1): 107-112, 2004
- PiTou Tian et al., Scientific Reports. 2: 261, 2012
- the first cleavable heterologous peptide and the second cleavable heterologous peptide both comprise, consist essentially of, or consist of an amino acid sequence independently selected from RGVFRR (SEQ ID NO: 3), RAKR; RKKR; RKYR; RRKR RRRR; RQRR; LSRR; RKRR; RHKR; RERR; RPRR; RARR; RS AR; LRKR; RTRR RTAR; RNTR; RLRR; RWRR; RGKR; RVKR; RHPR; RRGR; RVRR; RDRR; RTGR REAR; RFKR; RYKR; RHAR; RLLR; RVGR; RRAR; HPKR; RFPR; RRTR; RNQR; RSRR RRRK; RSIR; RTPR; RPAR; RNHR; RKTR; RKNR; RLKR; RNRR; RKSR; RMKR
- RVER RIKR; VKKR; RFRR RALR; MKKR; RVTR; NCSR; KRKR; RSSR; RMAR; KRRR; RRPR; TIKR; HLKR; RFER RASR; RRSR; VRRR; KAKR; RDKR; KVKR; RFLR; RLPR; RPPR; RHSR; RSGR; RICR HKKR; RSER; RLVR; RVPR; RFSR; RTIR; RLTR; RKAR; RAQR; RQMR; RFVR RSNR; RQPR; CVRR; RSYR; IKKR; RHVR; RLAR;
- RPLR IGKR
- VTKR RRHR
- RRNR VHKR
- RCPR RWPR
- SKER RIKK; RIFR; RVWR; LEGR; LKKR; VFRR; and IRKR.
- the first cleavable heterologous peptide and/or the second cleavable heterologous peptide are not RQKR, RTKR, LQKR, KTRR, KTKR, and KTRR.
- the insulin B-chain comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 2.
- the insulin C-peptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 4.
- the insulin A-chain comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 5.
- the E-insulin of the invention further comprises a signal peptide.
- the signal peptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1.
- the E-insulin comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 7.
- the E-insulin is a variant of SEQ ID NO: 7 having at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 changes (deletions, insertions, substitutions) that do not substantially alter (e.g., decrease no more than 5%, 10%, 15%, 20% of the E-insulin or wt insulin activity).
- the E-insulin comprises, consists essentially of, or consists of the amino acid sequence encoded by SEQ ID NO: 6.
- the insulin A-chain and the insulin B -chain are covalently linked by a disulfide bond.
- the insulin A-chain and the insulin B -chain are covalently linked by two disulfide bonds.
- the E-insulin of the invention further comprises an H10D substitution on the insulin B-chain.
- Another aspect of the invention provides a mature E-insulin resulting from cleavage of the E-insulin of the invention described herein, at the first cleavable heterologous peptide and said second cleavable heterologous peptide, wherein said insulin A-chain and said insulin B-chain are covalently linked by two disulfide bonds.
- the mature E-insulin comprises a first remnant sequence of the first cleavable heterologous peptide, optionally, the first remnant sequence is removed by a carboxypeptidase (such as carboxypeptidase E) in said mature E-insulin.
- a carboxypeptidase such as carboxypeptidase E
- the mature E-insulin does not have any remnant sequence of the first cleavable heterologous peptide after removal of such remnant sequence by a carboxypeptidase (such as carboxypeptidase E).
- a carboxypeptidase such as carboxypeptidase E
- Another aspect of the invention provides a cleaved insulin C-peptide resulting from cleavage of the E-insulin of the invention at the first cleavable heterologous peptide and the second cleavable heterologous peptide, wherein the cleaved insulin C-peptide comprises a remnant sequence of the second cleavable heterologous peptide; optionally, the second remnant sequence is removed by a carboxypeptidase (such as carboxypeptidase E) in the cleaved insulin C-peptide.
- a carboxypeptidase such as carboxypeptidase E
- Another aspect of the invention provides a polynucleotide encoding the E-insulin of the invention described herein.
- Another aspect of the invention provides a vector comprising the polynucleotide of the invention described herein.
- the vector comprises a transcriptional regulatory element, such as a promoter and/or enhancer, operably linked to a transcription cassette comprising the polynucleotide of the invention.
- a transcriptional regulatory element such as a promoter and/or enhancer
- the enhancer and/or the promoter is a muscle-specific control element.
- muscle specific control element refers to a nucleotide sequence that regulates expression of a coding sequence that is specific for expression in muscle tissue. These control elements include enhancers and/or promoters. Exemplary muscle specific control elements include a MCKH7 promoter, an MCK promoter, and a MCK enhancer.
- muscle-specific control element include human skeletal actin gene element, cardiac actin gene element, myocyte- specific enhancer binding factor MEF, muscle creatine kinase (MCK), tMCK (truncated MCK), myosin heavy chain (MHC), MHCK7 (a hybrid version of MHC and MCK), C5-12 (synthetic promoter), murine creatine kinase enhancer element, skeletal fast-twitch troponin C gene element, slow-twitch cardiac troponin C gene element, slow-twitch troponin I gene element, hypoxia- inducible nuclear factors, steroid- inducible element or glucocorticoid response element (GRE).
- MEF muscle creatine kinase
- MHC myosin heavy chain
- MHCK7 a hybrid version of MHC and MCK
- C5-12 synthetic promoter
- murine creatine kinase enhancer element skeletal fast-twitch troponin C gene element, slow-twitch
- the promoter comprises: (1) a constitutively active eukaryotic promoter, (2) a muscle-specific promoter, and/or (3) a synthetic promoter.
- the vector comprises two promoters.
- the vector comprises: (1) a first transcription cassette comprising the polynucleotide of the invention operably linked to a first promoter (e.g., a muscle- specific promoter such as MCK, or a constitutive promoter such as CBA or CAG); and, (2) a second transcription cassette comprising the polynucleotide of the invention operably linked to a second promoter, such as a synthetic promoter; wherein the polynucleotides of the invention in the first and the second transcription cassettes are independently selected from the E-insulin of the invention described herein.
- a first promoter e.g., a muscle- specific promoter such as MCK, or a constitutive promoter such as CBA or CAG
- a second transcription cassette comprising the polynucleotide of the invention operably linked to a second promoter, such as a synthetic promoter
- the muscle-specific promoter is MHCK7, CK8e, tMCK, (human) skeletal a- actin (HSA) promoter (including full length or shortedn HAS promoter, and chimeric HSA/CMV promoter consisting of a fragment of the HSA promoter and the CMV promoter), muscle creatine kinase (MCK/CKM) promoter or derivative thereof (including CK6, MHCK7, dMCK, tMCK, CK8 and CK8e), desmin gene promoter, human a- myosin heavy chain gene (aMHC) promoter, myosin light-chain promoter (MLC2v), cardiac troponin T promoter (cTnT), a chimeric promoter comprising the CMV-IE enhancer ligated to the 1.5-kbp fragment of the rat promoter MLC, and the AUSEx3 promoter developed from the human troponin I (TNNI1) gene.
- HSA skeletal a- actin
- the constitutive promoter is: CAG, CB, CB6, respiratory syncytial virus (RSV) promoter, cytomegalovirus (CMV) promoter, or elongation factor la (EFla) promoter.
- RSV respiratory syncytial virus
- CMV cytomegalovirus
- EFla elongation factor la
- the promoter is a synthetic promoter.
- Synthetic promoter is a technological approach in promoter design. This strategy enables one to engineer promoters with defined properties, such as size and the expression profile of the transgene.
- the development of synthetic promoters relies on computational algorithms, which are used to identify regulatory sequences and TFBSs within the genome, as well as to predict the promoter regions. For example, the binding sites for myogenic TFs are usually shorter than 10 bp, which allows one to create a library of constructs with different combinations of muscle- specific TFBSs.
- the synthetic promoter is the SPc5-12 promoter (Li et al., Nat. Biotechnol. 17(3):241-245, 1999).
- the SPc5-12 promoter consists of a combination of four muscle-specific TFBSs (TEF1, SRE, MEF1, and MEF2) and the core promoter (a fragment of the promoter of the chicken skeletal muscle a-actin gene). Its activity in muscle fibers is reportedly six-fold higher than that of the CMV promoter. Further, in vivo experiments confirmed that the SPc5-12 promoter is inactive in undifferentiated myoblasts and in various nonmuscle cell lines.
- the synthetic promoter is the SP-301 promoter (Liu et al., Plasmid. 106:102441, 2019).
- the SP-301 promoter is a combination of muscle- specific TFBSs, viral elements, and conserved cis-regulatory elements ligated in forward and reverse orientation.
- the SP-301 promoter is 6.6 times more active than the CMV promoter 2 days after intramuscular delivery of the construct in mice and remained active for at least a month. The tissue specificity of the SP-301 promoter was confirmed in transgenic mice.
- the synthetic promoter is the MH promoter.
- the MH promoter consists of the human desmin gene enhancer linked to the enhancer, the core promoter, and the first intron of the mouse Ckm gene.
- the MH promoter ensured the highest expression level in the muscle cell culture, being superior to the desmin and CMV promoters.
- AAV2/9 carrying a reporter gene delivered intravenously in mice under the control of the MH promoter has higher reporter activity in the cardiac and skeletal muscles than that of the desmin and CMV promoters. Further, the MH promoter does not induce transgene expression in the liver.
- the synthetic promoter is the Sk-CRM4/Des promoter, which is the regulatory module Sk-CRM4 ligated to the desmin promoter and the MVM intron.
- the Sk-CRM4 chimeric promoter enhanced the activity of the desmin promoter by 200-400 times in different skeletal muscles, the diaphragm, and the heart, while remaining inactive in non-target tissues.
- the SkCRM4/Des promoter attained a 25-173 times higher expression in different muscles as compared to the CMV promoter and also outperformed the Sk-CRM4/ SPc5-12 and SPc5-12 promoters. Therefore, the computationally designed Sk-CRM4/Des chimeric promoter demonstrated improved muscle- specific performance as compared to the other promoters commonly used for muscle gene therapy.
- the transcription cassette(s) further encodes a 5’-UTR region, a 3’-UTR region, and/or a polyA signal operably linked to the polynucleotide of the invention.
- the 5’-UTR region comprises an intron.
- Expression of the target gene such as E-insulin can be enhanced due to the presence of an intron in the vector.
- the intron is typically positioned between the promoter and the coding region. While not wishing to be bound by any particular theory, the presence of the intron is believed to increase RNA stability in the nucleus due to the incorporation of mRNA into the spliceosome and promotes efficient export of spliced mRNA from the nucleus to the cytoplasm.
- the introns contains regulatory sequences that affect tissue specificity and the expression level of the target gene.
- the intron is from the Ckm gene.
- the intron is the MVM intron.
- the 3’-UTR comprises a (600-bp) post-transcriptional regulatory element of the woodchuck hepatitis virus (WPRE) which can lead to an enhancement of transgene expression in muscles.
- WPRE woodchuck hepatitis virus
- WPRE is believed to promote mRNA export from the nucleus and prevents post-translational gene silencing.
- the AAV vector of the invention further comprises an miRNA detargeting sequence that suppresses expression of the target gene in a non-target tissue, such as liver or neuronal tissues.
- a non-target tissue such as liver or neuronal tissues.
- the binding sites for certain microRNA that are present only in the non-target organs are added to the 3’-UTR of the expression cassette (e.g., miRNA detargeting sites). If transgenic mRNA is expressed in a non-target organ, microRNA binds to such complementary detargeting sites on the transgene and initiates its degradation.
- the vector is an AAV (adeno-associated viral) vector further comprising a 5’ ITR and/or a 3’ ITR.
- AAV is a standard abbreviation for adeno-associated virus.
- Adeno-associated virus is a single- stranded DNA parvovirus that grows only in cells in which certain functions are provided by a co-infecting helper virus. Numerous serotypes of AAV have been characterized. General information and reviews of AAV can be found in, for example, Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169- 228, and Berns, 1990, Virology, pp. 1743-1764, Raven Press, (New York, incorporated herein by reference).
- AAV vector or “AAV vector genome (vg)” as used herein refers to a vector comprising one or more polynucleotides of interest (or transgenes) that are flanked by AAV terminal repeat sequences (ITRs).
- ITRs AAV terminal repeat sequences
- Another aspect of the invention provides an AAV viral particle comprising the AAV vector of the invention, encapsidated within a capsid.
- AAV virion or “AAV viral particle” refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector.
- the particle comprises a heterologous polynucleotide (i.e., a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell).
- production of AAV vector particle necessarily includes production of AAV vector, as such a vector is contained within an AAV vector particle.
- the capsid has a serotype with muscle tropism, such as tropism for skeletal muscle, smooth muscle, or cardiac muscle.
- the capsid has the serotype of AAV1, AAV2, AAV6, AAV7, AAV8, AAV9, AAV-DJ/8, AAV-RhlO, AAV-retro, AAV-PHP.B, AAV-PHP.eB, or AAV- PHP.S, or a genetically engineered AAV Capsid.
- rAAV Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692 (incorporated herein by reference).
- Other types of rAAV variants for example rAAV with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy 22(11): 1900-1909, 2014 (incorporated herein by reference).
- Another aspect of the invention provides a method of delivering an engineered insulin polypeptide to a muscle cell, the method comprising contacting the muscle cell with the AAV viral particle of the invention.
- the muscle cell is in an animal, such as a human or a nonhuman mammal.
- the animal has Type 1 or Type 2 diabetes, or hyperglycemia.
- Another aspect of the invention provides a method of treating a subject in need of treatment for a disease treatable by insulin, the method comprising administering to the subject a therapeutically effective amount of the AAV viral particle of the invention.
- the AAV viral particle is administered systemically, such as parental administration by injection, infusion or implantation.
- the AAV viral particle is administered by intramuscular injection or intravenous injection.
- the AAV viral particle is delivered intramuscularly.
- the subject has Type 1 diabetes.
- the subject has Type 2 diabetes.
- the subject has hyperglycemia.
- compositions such as a pharmaceutical composition, comprising the E-insulin polypeptide of the invention, the polynucleotide encoding the E-insulin polypeptide of the invention, the vector of the invention comprising the polynucleotide of the invention, the AAV vector genome of the invention comprising the polynucleotide of the invention, and/or the AAV viral particle of the invention encapsidating the AAV vector genome of the invention in a suitable capsid, such as a capsid with muscle tropism.
- a suitable capsid such as a capsid with muscle tropism.
- the composition of the invention is formulated for intramuscular injection or intravenous injection. In certain embodiments, the composition of the invention is formulated for systemic administration, such as parental administration by injection, infusion or implantation.
- the buffer agent comprises one or more of tris, tricine, Bis-tricine, HEPES, MOPS, TES, TAPS, PIPES, and CAPS.
- the buffer agent may comprise tris with pH 8.0 at concentration of about 5 mM to about 40 mM, or the buffer agent may comprise the tris with pH 8.0 at about 20 mM.
- the ionic strength agent comprises one or more of potassium chloride (KC1), potassium acetate, potassium sulfate, ammonium sulfate, ammonium chloride (NH4CI), ammonium acetate, magnesium chloride (MgCh), magnesium acetate, magnesium sulfate, manganese chloride (MnCh), manganese acetate, manganese sulfate, sodium chloride (NaCl), sodium acetate, lithium chloride (LiCl), and lithium acetate.
- the ionic strength agent comprises MgCh at a concentration of about 0.2 mM to about 4 mM; or the ionic strength agent comprises NaCl at a concentration of about 50 mM to about 500 mM; or the ionic strength agent comprises MgCh at a concentration of about 0.2 mM to about 4 mM and NaCl at a concentration of about 50 mM to about 500 mM, or the ionic strength agent comprises MgCh at a concentration of about 1 mM and NaCl at a concentration of about 200 mM.
- the surfactant comprises one or more of a sulfonate, a sulfate, a phosphonate, a phosphate, a Poloxamer, and a cationic surfactant.
- the Poloxamer comprises one or more of Poloxamer 124, Poloxamer 181, Poloxamer 184, Poloxamer 188, Poloxamer 237, Poloxamer 331, Poloxamer 338, and Poloxamer 407.
- the Poloxamer may be at a concentration of about 0.00001% to about 1%.
- An exemplary surfactant is Poloxamer 188 at a concentration of about 0.001%. 2.
- Recombinant AAV genomes of the invention comprise a polynucleotide or nucleic acid molecule of the invention, and one or more AAV ITRs flanking the polynucleotide or nucleic acid molecule.
- AAV DNA in the rAAV genomes may be from any AAV serotype for which a recombinant virus can be derived including, but not limited to, AAV serotypes AAV1, AAV2, AAV6, AAV7, AAV8, AAV9, AAV-DJ/8, AAV-RhlO, AAV-retro, AAV- PHP.B, AAV-PHP.eB, AAV-PHP.S, AAV-rh.10 or AAV-rh.74, or a genetically engineered AAV Capsid.
- the AAV viral particle has a serotype with muscle tropism, either exclusively, or preferentially.
- rAAV Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692.
- Other types of rAAV variants for example rAAV with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11): 1900-1909 (2014).
- the nucleotide sequences of the genomes of various AAV serotypes are known in the art.
- AAV-1, AAV-5, AAV-6, AAV-rh74, AAV-8 or AAV-9 may be used.
- the invention also provides DNA plasmids comprising rAAV vector genomes of the invention.
- the DNA plasmids can be transferred to cells permissible for infection with a helper virus of AAV (e.g., adenovirus, El- deleted adenovirus or herpes virus) for assembly of the rAAV genome into infectious viral particles.
- a helper virus of AAV e.g., adenovirus, El- deleted adenovirus or herpes virus
- rAAV particles in which an AAV genome to be packaged, rep and cap genes, and helper virus functions are provided to a cell are standard in the art, and is commonly known as the so-called the “triple transfection” method, even though the method of introduction may not necessarily be the traditional means for plasmid transfection.
- rAAV rAAV genome
- AAV rep and cap genes separate from (i.e., not in) the rAAV genome
- helper virus functions i.e., not in virus
- the AAV rep and cap genes may be from any AAV serotype for which recombinant virus can be derived and may be from a different AAV serotype than the rAAV genome ITRs, including, but not limited to, AAV serotypes AAV1, AAV2, AAV6, AAV7, AAV8, AAV9, AAV-DJ/8, AAV-RhlO, AAV-retro, AAV-PHP.B, AAV-PHP.eB, AAV-PHP.S, AAV-rh.10 or AAV-rh.74, or a genetically engineered AAV Capsid.
- a method of generating a packaging cell is to create a cell line that stably expresses all the necessary components for AAV particle production.
- a plasmid or multiple plasmids
- a plasmid comprising a rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes separate from the rAAV genome, and a selectable marker, such as a neomycin resistance gene, are integrated into the genome of a cell.
- AAV genomes have been introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al., Proc. Natl. Acad.
- packaging cells that produce infectious rAAV.
- packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells and PerC.6 cells (a cognate 293 line).
- packaging cells are cells that are not transformed cancer cells, such as low passage 293 cells (human fetal kidney cells transformed with El of adenovirus), MRC-5 cells (human fetal fibroblasts), WL38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells) and FRhL-2 cells (rhesus fetal lung cells).
- Recombinant AAV i.e., infectious encapsidated rAAV particles
- Recombinant AAV i.e., infectious encapsidated rAAV particles
- the rAAV may be purified by methods standard in the art such as by column chromatography or cesium chloride gradients. Methods for purifying rAAV vectors from helper virus are known in the art and include methods disclosed in, for example, Clark et al., Hum. Gene Ther., 10(6): 1031-1039 (1999); Schenpp and Clark, Methods Mol. Med., 69427- 443 (2002); U.S. Patent No. 6,566,118 and WO 98/09657.
- compositions comprising the E-insulin of the invention, the polynucleotide encoding the E-insulin of the invention, and/or the vector comprising the polynucleotide of the invention.
- the vector is an rAAV of the present invention.
- compositions described herein comprise rAAV in a pharmaceutically acceptable carrier.
- the compositions may also comprise other ingredients such as diluents and adjuvants.
- Acceptable carriers, diluents and adjuvants are nontoxic to recipients and are preferably inert at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, pluronics or polyethylene glycol (PEG).
- buffers such as phosphate, citrate, or other organic acids
- antioxidants such as ascorbic acid
- Titers of rAAV to be administered in methods of the invention will vary depending, for example, on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be determined by methods standard in the art.
- Exemplary titers of rAAV may range from about 1 x 10 6 , about 1 x 10 7 , about 1 x 10 8 , about 1 x 10 9 , about 1 x IO 10 , about 1 x 10 11 , about 1 x 10 12 , about 1 x 10 13 to about 1 x 10 14 or more DNase resistant particles (DRP) per ml.
- DNase resistant particles DNase resistant particles
- Dosages may also be expressed in units of viral genomes (vg).
- the titers of rAAV may be determined by the supercoiled plasmid quantitation standard or the linearized plasmid quantitation standard.
- the disclosure provides methods of measuring the titer of an AAV vector, comprising tittering the AAV vector with PCR with a first primer and a second primer. In another embodiment, methods of measuring the titer of an AAV vector, comprising tittering the AAV vector with a probe.
- the in vivo methods comprise the step of administering an effective dose, or effective multiple doses, of a composition comprising a rAAV of the invention to an animal (including a human being) in need thereof. If the dose is administered prior to development of a disorder/disease, the administration is prophylactic. If the dose is administered after the development of a disorder/disease, the administration is therapeutic.
- an effective dose is a dose that alleviates (eliminates or reduces) at least one symptom associated with the disorder/disease state being treated, that slows or prevents progression to a disorder/disease state, that slows or prevents progression of a disorder/disease state, that diminishes the extent of disease, that results in remission (partial or total) of disease, and/or that prolongs survival.
- An example of a disease contemplated for prevention or treatment with methods of the invention is T1DM, T2DM, or hyperglycemia.
- compositions of the invention can be prepared as injectable formulations or as topical formulations to be delivered to the muscles by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and can be used in the practice of the invention.
- the rAAV can be used with any pharmaceutically acceptable carrier for ease of administration and handling.
- the application is directed to a formulation that comprises an rAAV that comprises a suitable AAV capsid with muscle tropism, such as AAV9, a buffer agent, an ionic strength agent, and a surfactant.
- the rAAV is at a concentration of 1.0 x 10 12 vg/mL to about 1.0 x 10 16 vg/mL, or about 1.0 x 10 12 vg/mL to about 5.0 x 10 14 vg/mL. In another embodiment, the rAAV is at a concentration of about 5.0 x 10 12 vg/mL to about 1.0 x 10 14 vg/mL based on a supercoiled plasmid as the quantitation standard.
- the rAAV is at a concentration of about 5.0 x 10 12 vg/mL to about 1.0 x 10 14 vg/mL based on a linearized plasmid as the quantitation standard.
- the rAAV is at a concentration of about 2.0 x 10 13 vg/mL based on a supercoiled plasmid as the quantitation standard.
- the concentration of rAAV in the composition or formulation is from 1.0 x 10 13 vg/mL to 2.0 x 10 14 vg/mL based on a supercoiled plasmid as the quantitation standard.
- the concentration is 2.0 x 10 13 vg/mL, 4.0 x 10 13 vg/mL, or 5.0 x 10 13 vg/mL based on a supercoiled plasmid as the quantitation standard.
- the buffer agent comprises one or more of tris, tricine, Bis- tricine, HEPES, MOPS, TES, TAPS, PIPES, and CAPS.
- the buffer agent comprises tris with pH 8.0 at concentration of about 5 mM to about 40 M.
- the buffer agent comprises tris with pH 8.0 at about 20 mM.
- the ionic strength agent comprises one of more of potassium chloride (KC1), potassium acetate, potassium sulfate, ammonium sulfate, ammonium chloride (NH4CI), ammonium acetate, magnesium chloride (MgCh), magnesium acetate, magnesium sulfate, manganese chloride (MnCh), manganese acetate, manganese sulfate, sodium chloride (NaCl), sodium acetate, lithium chloride (LiCl), and lithium acetate.
- the ionic strength agent comprises MgCh at a concentration of about 0.2 mM to about 4 mM. In another embodiment, the ionic strength agent comprises NaCl at a concentration of about 50 mM to about 500 mM. In another embodiment, the ionic strength agent comprises MgCh at a concentration of about 0.2 mM to about 4 mM and NaCl at a concentration of about 50 mM to about 500 mM. In another embodiment, the ionic strength agent comprises MgCh at a concentration of about 1 mM and NaCl at a concentration of about 200 mM.
- the surfactant comprises one or more of a sulfonate, a sulfate, a phosphonate, a phosphate, a Poloxamer, and a cationic surfactant.
- the Poloxamer comprises one or more of Poloxamer 124, Poloxamer 181, Poloxamer 184, Poloxamer 188, Poloxamer 237, Poloxamer 331, Poloxamer 338, and Poloxamer 407.
- the surfactant comprises the Poloxamer at a concentration of about 0.00001% to about 1%.
- the surfactant comprises Poloxamer 188 at a concentration of about 0.001%.
- solutions in an adjuvant such as sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions.
- aqueous solutions can be buffered, if desired, and the liquid diluent first rendered isotonic with saline or glucose.
- Solutions of rAAV as a free acid (DNA contains acidic phosphate groups) or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxpropylcellulose.
- a dispersion of rAAV can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils.
- these preparations contain a preservative to prevent the growth of microorganisms.
- the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating actions of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), suitable mixtures thereof, and vegetable oils.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of a dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, phenol, chlorobutanol, sorbic acid, thimerosal and the like. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating rAAV in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization.
- dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and the freeze drying technique that yield a powder of the active ingredient plus any additional desired ingredient from the previously sterile-filtered solution thereof.
- compositions may be by routes standard in the art including, but not limited to, intramuscular, parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or vaginal.
- routes standard in the art including, but not limited to, intramuscular, parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or vaginal.
- Route(s) of administration and serotype(s) of AAV components of the rAAV (in particular, the AAV ITRs and capsid protein) of the invention may be chosen and/or matched by those skilled in the art taking into account the infection and/or disease state being treated and the target cells/tissue(s) that are to express the E-insulin.
- systemic administration is administration into the circulatory system so that the entire body is affected.
- Systemic administration includes enteral administration such as absorption through the gastrointestinal tract and parental administration through injection, infusion or implantation.
- administration of rAAV of the present invention may be accomplished by using any physical method that will transport the rAAV recombinant vector into the target tissue of an animal.
- Administration according to the invention includes, but is not limited to, injection into muscle, the bloodstream and/or directly into the liver. Simply resuspending a rAAV in phosphate buffered saline has been demonstrated to be sufficient to provide a vehicle useful for muscle tissue expression, and there are no known restrictions on the carriers or other components that can be co-administered with the rAAV (although compositions that degrade DNA should be avoided in the normal manner with rAAV).
- Capsid proteins of a rAAV may be modified so that the rAAV is targeted to a particular target tissue of interest such as muscle. See, for example, WO 02/053703, the disclosure of which is incorporated by reference herein.
- Transduction with rAAV may also be carried out in vitro.
- desired target muscle cells are removed from the subject, transduced with rAAV and reintroduced into the subject.
- syngeneic or xenogeneic muscle cells can be used where those cells will not generate an inappropriate immune response in the subject.
- cells can be transduced in vitro by combining rAAV with muscle cells, e.g., in appropriate media, and screening for those cells harboring the DNA of interest using conventional techniques such as Southern blots and/or PCR, or by using selectable markers.
- Transduced cells can then be formulated into pharmaceutical compositions, and the composition introduced into the subject by various techniques, such as by intramuscular, intravenous, subcutaneous and intraperitoneal injection, or by injection into smooth and cardiac muscle, using e.g., a catheter.
- Transduction of cells with rAAV of the invention results in sustained expression of E- insulin.
- the present invention thus provides methods of administering/delivering rAAV which express E-insulin to a mammalian subject, preferably a human being.
- These methods include transducing tissues (including, but not limited to, tissues such as muscle, organs such as liver and brain, and glands such as salivary glands) with one or more rAAV of the present invention. Transduction may be carried out with gene cassettes comprising tissue specific control elements.
- one embodiment of the invention provides methods of transducing muscle cells and muscle tissues directed by muscle specific control elements, including, but not limited to, those derived from the actin and myosin gene families, such as from the myoD gene family [See Weintraub et al., Science, 251: 761-766 (1991)], the myocyte- specific enhancer binding factor MEF-2 [Cseijesi and Olson, Mol Cell Biol 11: 4854-4862 (1991)], control elements derived from the human skeletal actin gene [Muscat et al., Mol Cell Biol, 7: 4089-4099 (1987)], the cardiac actin gene, muscle creatine kinase sequence elements [See Johnson et al., Mol Cell Biol, 9:3393-3399 (1989)] and the murine creatine kinase enhancer (mCK) element, control elements derived from the skeletal fast-twitch troponin C gene, the slow-twitch cardiac troponin C gene and the slow-tw
- Muscle tissue is an attractive target for in vivo DNA delivery, because it is not a vital organ and is easy to access.
- the invention contemplates sustained expression of E-insulin mRNAs from transduced myofibers.
- muscle cell or “muscle tissue” is meant a cell or group of cells derived from muscle of any kind (for example, skeletal muscle and smooth muscle, e.g. from the digestive tract, urinary bladder, blood vessels or cardiac tissue). Such muscle cells may be differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes and cardiomyoblasts.
- transduction is used to refer to the administration/delivery of a polynucleotide of interest (e.g., a polynucleotide sequence encoding E-insulin) to a recipient cell either in vivo or in vitro, via a replication-deficient rAAV described resulting in expression of E-insulin by the recipient cell.
- a polynucleotide of interest e.g., a polynucleotide sequence encoding E-insulin
- Combination therapies are also contemplated by the invention.
- Combination as used herein includes both simultaneous treatment or sequential treatments.
- Combinations of methods of the invention with standard medical treatments are specifically contemplated, as are combinations with novel therapies.
- the combinations include administering to a subject one or more treatment suitable for treatment by insulin, before, simultaneous, or after the administration of an rAAV of the invention to a subject in need thereof.
- the treatment suitable for treatment by insulin comprises medical nutrition therapy (MNT), a process by which the dietary plan of the subject or patient is tailored based on medical, lifestyle, and personal factors.
- MNT medical nutrition therapy
- the treatment suitable for treatment by insulin comprises weight reduction treatment, e.g., for overweight (BMI >25 to 29.9 kg/m 2 ) or obese (BMI >30 kg/m 2 ) patients with type 2 diabetes.
- the weight reduction treatment may comprise reducing caloric intake, increasing physical activity, and/or behavior modification to achieve weight loss.
- the treatment suitable for treatment by insulin comprises diet or diet control.
- the treatment suitable for treatment by insulin comprises exercise, such as aerobic exercise that may include 30 to 60 minutes of moderate-intensity aerobic activity (40 to 60 percent VO2 max) on most days of the week (e.g., at least 150 minutes of moderate-intensity aerobic exercise per week, spread over at least three days per week, with no more than two consecutive days without exercise); and/or resistance training (e.g., exercise with free weights or weight machines at least twice per week).
- exercise such as aerobic exercise that may include 30 to 60 minutes of moderate-intensity aerobic activity (40 to 60 percent VO2 max) on most days of the week (e.g., at least 150 minutes of moderate-intensity aerobic exercise per week, spread over at least three days per week, with no more than two consecutive days without exercise); and/or resistance training (e.g., exercise with free weights or weight machines at least twice per week).
- the treatment suitable for treatment by insulin comprises a pharmacological intervention that may comprise one or more of: metformin (e.g., 500 mg once daily with the evening meal and, if tolerated, add a second 500 mg dose with breakfast), GLP-1 receptor agonists (such as liraglutide, semaglutide, dulaglutide), SGLT2 inhibitor (such as empagliflozin, canagliflozin, and dapagliflozin), sulfonylurea (such as glipizide or glimepiride), DPP-4 inhibitor, repaglinide, or pioglitazone.
- metformin e.g., 500 mg once daily with the evening meal and, if tolerated, add a second 500 mg dose with breakfast
- GLP-1 receptor agonists such as liraglutide, semaglutide, dulaglutide
- SGLT2 inhibitor such as empagliflozin, canagliflozin, and dapagliflo
- E-insulin engineered insulin
- AACTAG SEQ ID NO : 6
- B-chain FVNQHLCGSHLVEALYLVCGERGFFYTPKTRR ( SEQ ID NO : 2 )
- A-chain GIVEQCCTSICSLYQLENYCN ( SEQ ID NO : 5 )
- terminal one or two basic residue(s) in the B-chain and the C-peptide could be removed by enzymes such as carboxy peptidase after cleavage, and may or may not be present in the mature B-chain or C-peptide.
- sequence of RGVFRR (SEQ ID NO: 3) was inserted at the juncture of the natural human insulin B-chain and C-peptide as the first heterologous peptide, and again at the juncture of the natural human insulin C-peptide and A-chain as the second heterologous peptide, though it is not required for the two heterologous peptides to be the same.
- the polynucleotide of SEQ ID NO: 6 was first inserted into an expression vector to show that E-insulin can be expressed in vitro.
- the E-insulin insert was released from the plasmid backbone, as were resolved on electrophoresis.
- FIG. 5 shows that the E-insulin can be secreted and further be processed to mature forms, the same way the wild-type FL insulin can. Indeed, a majority of the E-insulin appeared to be processed to the mature form, which has a smaller molecular weight, and comigrates with commercial insulin product Novolin. Meanwhile, FL insulin has a significant portion remain unprocessed to the mature form, and remains full length (including the C- peptide).
- FIG. 7 shows that the secreted E-insulin was capable of being a potent inducer in muscle cells (myoblasts) by promoting their differentiation into myotubes.
- IF immunoflurescent
- the polynucleotide of SEQ ID NO: 6 is then inserted into an AAV viral vector, under the control of one of the promoters of the invention, such as a constitutively active eukaryotic promoter, a muscle-specific promoter (such as a CK8 promoter), and/or a synthetic promoter (such as CAG, CBA, or derivative thereof).
- a constitutively active eukaryotic promoter such as a muscle-specific promoter (such as a CK8 promoter), and/or a synthetic promoter (such as CAG, CBA, or derivative thereof).
- Such transcription unit may optionally further comprise a 5’ UTR region, a heterologous intron to enhance expression of the insulin, a 3’ UTR region, and/or a polyA tail.
- the AAV vector genome encompassing such a transcription unit is flanked by at least one functional ITR, such as a 5’ ITR and/or a 3’ ITR from AAV2.
- the AAV vector genome can be encapsidated in any AAV capsid with preferential tropism for muscle tissues, such as skeletal muscle, smooth muscle (e.g., diaphragm), and/or cardiac muscle.
- AAV capsids include AAV1, AAV2, AAV6, AAV7, AAV8, AAV9, AAV-DJ/8, AAV-RhlO, AAV-retro, AAV-PHP.B, AAV-PHP.eB, or AAV- PHP.S, or a genetically engineered AAV Capsid.
- AAV9 capsid may be used.
- AAV viral particles can be produced using any standard methods, such as the triple transfection method in a host cell (e.g., HEK293) that permits assembling of AAV viral particles from the AAV vector genome described above in one vector, AAV rep and cap genes on a second vector, and helper genes for AAV packaging in a 3 rd vector.
- a host cell e.g., HEK293
- helper genes for AAV packaging in a 3 rd vector e.g., HEK293
- the harvested AAV viral particles can then be tittered and administered to an animal or subject in need thereof, such as one having Type 1 diabetes (T1DM), Type 2 diabetes (T2DM), and/or hyperglycemia.
- T1DM Type 1 diabetes
- T2DM Type 2 diabetes
- hyperglycemia hyperglycemia
- the injection can be intramuscular injection (z.m.).
- the animal or subject receiving such AAV injection can produce the E-insulin of the invention, that can be secreted into the blood stream from muscle tissues expressing such E- insulin, thereby treating T1DM, T2DM, and/or hyperglycemia.
- This example demonstrates intramuscular secretion of the subject human insulin from muscle tissue, and the effect of such muscle-secreted insulin in blood glucose reduction.
- diabetic mice were intramuscularly dosed with an AAV vector harboring a polynucleotide encoding an E-Insulin of the disclosure.
- Experimental diabetes was induced in 6-week old C57BL6/J mice to develop diabetes, by inducing with Streptozotocin (about 50 mg/kg) in 0.1 M Citrate buffer at pH4.5 daily IP injection for 5 consecutive days. After Streptozotocin treatment, mice were allowed to develop diabetes for two weeks until they reached fasting blood glucose ranging between 300-400 mg/dL.
- An AAV9 vector harboring an E-insulin coding sequence was injected intramuscularly in such diabetic mice, with the AAV9 viral particles suspended in about 200 pL of PBS buffer, which total volume was split between muscles of the two hind limbs of each experimental animal.
- Three AAV doses comprising about 2xl0 13 (2E13) vg/kg, about 2xl0 12 (2E12) vg/kg, and about 2xlO n (2E11) vg/kg were used for the study with controls.
- fasting blood glucose was measured in all animals using a handheld glucometer on a weekly basis. Preliminary analysis of the gathered data showed reduction in fasting blood glucose levels in animals intramuscularly dosed with the AAV9 viral particles harboring the E-Insulin coding sequence (data not shown).
Abstract
The invention described herein provides an engineered insulin polypeptide comprising two cleavable peptides interposed between the insulin B-chain and the C-peptide, and between the C-peptide and the insulin A-chain to secrete active insulin from muscle cells. Also provides are polynucleotide encoding the engineered insulin for intramuscular delivery through Adeno Associated Virus (AAV) vectors, and the use thereof to treat diseases such as diabetes, hyperglycemia and other hyperglycemia-related diseases.
Description
AAV-Mediated Intramuscular Delivery of Insulin
REFERENCE TO RELATED APPLICATION
This application claims priority to and the benefit of the filing date of U.S. Provisional Patent Application No. 63/396,861, filed on August 10, 2022, the entire contents of which (including any drawings and sequences) are incorporated herein by reference.
BACKGROUND OF THE INVENTION
Eukaryotic secreted proteins are generally processed and secreted via either the constitutive pathway or the regulated pathway.
Insulin is one of many secreted proteins in mammals. It is synthesized as an inactive preproinsulin having a signal peptide. The preproinsulin is translocated directly into the rough endoplasmic reticulum (RER), where its signal peptide is removed by signal peptidase to form proinsulin. As the proinsulin naturally folds, a C-terminal sequence called “A-chain” and an N-terminal sequence called “B-chain” become covalently linked together with three disulfide bonds (with one of the three being an intra-chain disulfide bond linking two Cys residues of the A-chain). This folded proinsulin then transits through the Golgi apparatus, and is packaged into specialized secretory vesicles. Within such granules, proinsulin is cleaved by specialized peptidases called proprotein convertase 1/3 and proprotein convertase 2, removing the middle part of the protein, called the “C-peptide.” Finally, carboxypeptidase E removes two pairs of amino acids from the protein’s ends, resulting in active insulin - the insulin A- and B- chains, connected with two disulfide bonds.
This process only occurs in the secretory vesicles of pancreatic P-cells in mammals, which secretory vesicles contain all the requisite processing enzymes described above. In cells with only the constitutive pathway, there are no such specialized proinsulin processing enzymes. Thus any synthesized preproinsulin there (if any) will not be processed into mature insulin for release outside the cells.
SUMMARY OF THE INVENTION
One aspect of the invention provides an engineered insulin polypeptide (E-insulin) engineered from a wild-type insulin sequence in a mammal, comprising: (a) a first cleavable heterologous peptide, between the insulin B-chain and the insulin C-peptide of the wild-type insulin; and, (b) a second cleavable heterologous peptide, between the insulin C-peptide and
the insulin A-chain of the wild-type insulin; wherein the first and the second cleavable heterologous peptides are both native sequences of the mammal.
In certain embodiments, the mammal is a human.
In certain embodiments, the first and the second cleavable heterologous peptides are both cleavable by a serine endoprotease expressed in muscle tissues.
In certain embodiments, the serine endoprotease is a subtilisin-like endoprotease, such as furin, PACE4, PC4, PC5/6, or LPC/PC8.
In certain embodiments, the first cleavable heterologous peptide and the second cleavable heterologous peptide independently comprise a sequence motif Arg-Xaa-Xaa-Arg (wherein Xaa is any amino acid) or Lys/Arg-Arg.
In certain embodiments, the serine endoprotease is present or expressed in trans-Golgi network (TGN), such as TGN of muscle tissue / cell.
In certain embodiments, the serine endoprotease is Furin.
In certain embodiments, the first cleavable heterologous peptide and the second cleavable heterologous peptide both comprise, consist essentially of, or consist of an amino acid sequence independently selected from RGVFRR (SEQ ID NO: 3); RAKR; RKKR; RKYR; RRKR RRRR; RQRR; LSRR; RKRR; RHKR; RERR; RPRR; RARR; RS AR; LRKR; RTRR REAR; RNTR; RLRR; RWRR; RGKR; RVKR; RHPR; RRGR; RVRR; RDRR; RTGR REAR; RFKR; RYKR; RHAR; RLLR; RVGR; RRAR; HPKR; RFPR; RRTR; RNQR; RSRR RRRK; RSIR; RTPR; RPAR; RNHR; RKTR; RKNR; RLKR; RNRR; RKSR; RMKR; RNKR RQQR; RIRR; REIR; REKR; RMRR; RPDR; RIVR; RPKR; RLKK; RSKR; RVAR; RGPR RVCR; RAPR; RQIR; RYRR; RKIR; RMIR; RVRK; RRVR; RCQR; RCKR; VRKR; RPVR RHTR; RCRR; RGRR; RISR; RAAR; RLGR; RYPR; RAGR; RIIR; KSAR; VSRR; RQCR RVKK; RIGR; RTTR; RHRR; WAR; RSHR; RYSR; RCIR; RCYR; RFRK; RYFR; RTMR RHGR; RSPR; RETR; RKFR; RHLR; RKGR; RRKK; RWKR; RVLR; RIKR; VKKR; RFRR RALR; MKKR; RVTR; NCSR; KRKR; RSSR; RMAR;
KRRR; RRPR; TIKR; HLKR; RFER RASR; RRSR; VRRR; KAKR; RDKR; KVKR; RFLR; RLPR; RPPR; RHSR; RSGR; RICR HKKR; RSLR; RLVR; RVPR; RFSR; RTIR; RLTR; RKAR; RAQR; RQMR; RFVR RSNR; RQPR; CVRR; RSYR; IKKR; RHVR; REAR;
RPLR; IGKR; VTKR; RRHR; RRNR VHKR; RCPR; RWPR; SKER; RIKK; RIFR; RVWR; LEGR; LKKR; VFRR; IRKR.
In certain embodiments, the insulin B-chain comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 2.
In certain embodiments, the insulin C-peptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 4.
In certain embodiments, the insulin A-chain comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 5.
In certain embodiments, the E-insulin of the invention further comprises a signal peptide.
In certain embodiments, the signal peptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1.
In certain embodiments, the insulin A-chain and the insulin B-chain are covalently linked by a disulfide bond.
In certain embodiments, the insulin A-chain and the insulin B-chain are covalently linked by two disulfide bonds.
In certain embodiments, the E-insulin of the invention further comprises an H10D substitution on the insulin B-chain.
Another aspect of the invention provides a mature E-insulin resulting from cleavage of the E-insulin of the invention described herein, at the first cleavable heterologous peptide and said second cleavable heterologous peptide, wherein said insulin A-chain and said insulin B-chain are covalently linked by two disulfide bonds.
In certain embodiments, the mature E-insulin comprises a first remnant sequence of the first cleavable heterologous peptide, optionally, the first remnant sequence (and further optionally the last one or two basic residue(s) at the C-terminus of SEQ ID NO: 2) is removed by a carboxypeptidase (such as carboxypeptidase E) in said mature E-insulin.
Another aspect of the invention provides a cleaved insulin C-peptide resulting from cleavage of the E-insulin of the invention at the first cleavable heterologous peptide and the second cleavable heterologous peptide, wherein the cleaved insulin C-peptide comprises a remnant sequence of the second cleavable heterologous peptide; optionally, the second remnant sequence (and further optionally the last one or two basic residue(s) at the C- terminus of SEQ ID NO: 4) is removed by a carboxypeptidase (such as carboxypeptidase E) in the cleaved insulin C-peptide.
Another aspect of the invention provides a polynucleotide encoding the E-insulin of the invention described herein.
Another aspect of the invention provides a vector comprising the polynucleotide of the invention described herein.
In certain embodiments, the vector comprises a promoter operably linked to a transcription cassette comprising the polynucleotide of the invention.
In certain embodiments, the promoter comprises: (1) a constitutively active eukaryotic promoter, (2) a muscle-specific promoter, and/or (3) a synthetic promoter.
In certain embodiments, the vector comprises two promoters.
In certain embodiments, the vector comprises: (1) a first transcription cassette comprising the polynucleotide of the invention operably linked to a first promoter (e.g., a muscle- specific promoter such as MCK, or a constitutive promoter such as CBA or CAG); and, (2) a second transcription cassette comprising the polynucleotide of the invention operably linked to a second promoter, such as a synthetic promoter; wherein the polynucleotides of the invention in the first and the second transcription cassettes are independently selected from the E-insulin of the invention described herein.
In certain embodiments, the transcription cassette(s) further encodes a 5’-UTR region, a 3’-UTR region, and/or a polyA signal operably linked to the polynucleotide of the invention.
In certain embodiments, the vector is an AAV (adeno-associated viral) vector further comprising a 5’ ITR and/or a 3’ ITR.
Another aspect of the invention provides an AAV viral particle comprising the AAV vector of the invention, encapsidated within a capsid.
In certain embodiments, the capsid has a serotype with muscle tropism, such as tropism for skeletal muscle, smooth muscle, or cardiac muscle.
In certain embodiments, the capsid has the serotype of AAV1, AAV2, AAV6, AAV7, AAV8, AAV9, AAV-DJ/8, AAV-RhlO, AAV-retro, AAV-PHP.B, AAV-PHP.eB, or AAV- PHP.S, or a genetically engineered AAV Capsid.
Another aspect of the invention provides a method of delivering an engineered insulin polypeptide to a muscle cell, the method comprising contacting the muscle cell with the AAV viral particle of the invention.
In certain embodiments, the muscle cell is in an animal, such as a human or a nonhuman mammal.
In certain embodiments, the animal has Type 1 or Type 2 diabetes, or hyperglycemia.
Another aspect of the invention provides a method of treating a subject in need of treatment for a disease treatable by insulin, the method comprising administering to the subject a therapeutically effective amount of the AAV viral particle of the invention.
In certain embodiments, the AAV viral particle is delivered intramuscularly.
In certain embodiments, the subject has Type 1 diabetes.
In certain embodiments, the subject has Type 2 diabetes.
In certain embodiments, the subject has hyperglycemia.
It should be understood that any one embodiment of any one of the aspects of the invention above, including specific embodiments described only in one section of the application, can be combined with one or more additional embodiments.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic (not to scale) illustration of the synthesis and processing of one embodiment of the engineered insulin (E-insulin) of the invention.
FIG. 2 is a schematic (not to scale) illustration of a more detailed structure of the one embodiment of the E-insulin of the invention depicted in FIG. 1.
FIG. 3 is a schematic (not to scale) illustration of a wild-type insulin structure for comparison with that of the E-insulin of FIG. 2.
FIG. 4 is an electrophoresis image showing the plasmid constructs encoding with the full-length wild-type (FE) human insulin, or one E-insulin of the invention. The E-insulin insert after restriction enzyme digestion is slightly larger than that of the FL insulin.
FIG. 5 shows that the processed mature insulin (E-insulin) were produced and secreted from mouse C2C12 muscle cells.
FIG. 6 shows that the C-peptide was secreted and released from the E-insulin or FL insulin from mouse C2C12 muscle cells.
FIG. 7 shows potency of secreted E-insulin in muscle cells by eliciting differentiation of C2C12 myoblast muscle cells into myotubes. Immunohistochemical localization of myosin heavy chain is used as molecular marker for myotube differentiation. The DAPI standing shows the locations of the muscle cell nuclei.
DETAILED DESCRIPTION OF THE INVENTION
1. Overview
The invention described herein provides an engineered insulin (E-insulin) construct and the E-insulin encoded thereby, wherein the E-insulin can be processed in vivo, in cells (such as muscle cells) that do not otherwise process wild-type preproinsulin to mature / active insulin. The invention is partly based on the introduction of two cleavable heterologous peptides that flanks the C-peptide in the E-insulin precursor, such that such cleavable heterologous peptides can be cleaved in the cells (e.g., muscle cells) to release mature insulin.
One salient feature of the E-insulin of the invention is that such cleavable heterologous peptides are both native sequences of the mammal. While not wishing to be bound by any particular theory, it is believed that the E-insulin with such cleavable heterologous peptides has reduced risk (if not without any risk) of causing host immune response, such as T- and B-cell mediated cellular and humoral immune responses against the E-insulin as both are native sequence of the mammal.
Thus, one aspect of the invention provides an engineered insulin polypeptide (E- insulin) engineered from a wild-type insulin sequence in a mammal, comprising: (a) a first cleavable heterologous peptide, between the insulin B-chain and the insulin C-peptide of the wild-type insulin; and, (b) a second cleavable heterologous peptide, between the insulin C- peptide and the insulin A-chain of the wild-type insulin; wherein the first and the second cleavable heterologous peptides are both native sequences of the mammal.
As used herein, “native sequences of the mammal” includes naturally existing sequences in the mammal. Such naturally existing sequences are unlikely to trigger undesirable host animal immune response, since such sequences are deemed self-antigens with respect to the host animal.
In certain embodiments, the mammal is a human. In certain embodiments, the mammal is a non-human animal, such as a rodent (such as a mouse, a rat, a rabbit, a hamster, a guinea pig, etc), pets (e.g., all breeds of dogs and cats and pet mammals), a livestock mammal (such as a horse, a sheep, a goat, a pig, a cow / bull), or a non-human primate, such as a monkey (e.g., a cynomolgus monkey, a rehesus monkey etc).
According to the invention, the E-insulin is engineered from the wild-type (wt) insulin of the mammal. For example, an E-insulin of the invention for human is based on /
engineered from the wild-type human insulin sequence, and the cleavable heterologous peptides are also from human.
The cleavable heterologous peptides are “heterologous,” partly because these sequences / peptides do not originate from insulin or its precursor thereof.
Any cleavable heterologous peptides may be used in the E-insulin of the invention, provided that they are cleavable by an enzyme expressed inside the target cell in which such E-insulin is to be expressed.
In certain embodiments, the first and the second cleavable heterologous peptides are both cleavable by a serine endoprotease expressed in muscle tissues.
For example, in certain embodiments, the serine endoprotease is a subtilisin-like endoprotease, such as furin, PACE4, PC4, PC5/6, or LPC/PC8.
In certain embodiments, the first cleavable heterologous peptide and the second cleavable heterologous peptide independently comprise a sequence motif Arg-Xaa-Xaa-Arg (wherein Xaa is any amino acid) or Lys/Arg-Arg.
In certain embodiments, the serine endoprotease is present or expressed in trans-Golgi network (TGN), such as TGN of muscle tissue / cell.
In certain embodiments, the serine endoprotease is Furin.
Furin is also known as PACE (Paired basic Amino acid Cleaving Enzyme). It is a member of family S8, and is a member of the subtilisin-like proprotein convertase family. The members of this family are proprotein convertases that process latent precursor proteins into their biologically active products. Furin is a calcium-dependent serine endoprotease that can efficiently cleave precursor proteins at their paired basic amino acid processing sites. The furin substrates and the locations of furin cleavage sites in protein sequences can be predicted by two bioinformatics methods: ProP (Duckert et al., Protein Engineering, Design & Selection 17 (1): 107-112, 2004) and PiTou (Tian et al., Scientific Reports. 2: 261, 2012), both incorporated herein by reference.
In certain embodiments, the first cleavable heterologous peptide and the second cleavable heterologous peptide both comprise, consist essentially of, or consist of an amino acid sequence independently selected from RGVFRR (SEQ ID NO: 3), RAKR; RKKR; RKYR; RRKR RRRR; RQRR; LSRR; RKRR; RHKR; RERR; RPRR; RARR; RS AR; LRKR; RTRR RTAR; RNTR; RLRR; RWRR; RGKR; RVKR; RHPR; RRGR; RVRR; RDRR; RTGR REAR; RFKR; RYKR; RHAR; RLLR; RVGR; RRAR; HPKR; RFPR;
RRTR; RNQR; RSRR RRRK; RSIR; RTPR; RPAR; RNHR; RKTR; RKNR; RLKR; RNRR; RKSR; RMKR; RNKR RQQR; RIRR; REIR; REKR; RMRR; RPDR; RIVR; RPKR; RLKK; RSKR; RVAR; RGPR RVCR; RAPR; RQIR; RYRR; RKIR; RMIR; RVRK; RRVR; RCQR; RCKR; VRKR; RPVR RHTR; RCRR; RGRR; RISR; RAAR; RLGR; RYPR; RAGR; RIIR; KSAR; VSRR; RQCR RVKK; RIGR; RTTR; RHRR; WAR; RSHR; RYSR; RCIR; RCYR; RFRK; RYFR; RTMR RHGR; RSPR; RETR; RKFR; RHER; RKGR; RRKK; RWKR;
RVER; RIKR; VKKR; RFRR RALR; MKKR; RVTR; NCSR; KRKR; RSSR; RMAR; KRRR; RRPR; TIKR; HLKR; RFER RASR; RRSR; VRRR; KAKR; RDKR; KVKR; RFLR; RLPR; RPPR; RHSR; RSGR; RICR HKKR; RSER; RLVR; RVPR; RFSR; RTIR; RLTR; RKAR; RAQR; RQMR; RFVR RSNR; RQPR; CVRR; RSYR; IKKR; RHVR; RLAR;
RPLR; IGKR; VTKR; RRHR; RRNR VHKR; RCPR; RWPR; SKER; RIKK; RIFR; RVWR; LEGR; LKKR; VFRR; and IRKR.
In certain embodiments, the first cleavable heterologous peptide and/or the second cleavable heterologous peptide are not RQKR, RTKR, LQKR, KTRR, KTKR, and KTRR.
In certain embodiments, the insulin B-chain comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 2.
In certain embodiments, the insulin C-peptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 4.
In certain embodiments, the insulin A-chain comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 5.
In certain embodiments, the E-insulin of the invention further comprises a signal peptide.
In certain embodiments, the signal peptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1.
In certain embodiments, the E-insulin comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 7. In certain embodiments, the E-insulin is a variant of SEQ ID NO: 7 having at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 changes (deletions, insertions, substitutions) that do not substantially alter (e.g., decrease no more than 5%, 10%, 15%, 20% of the E-insulin or wt insulin activity).
In certain embodiments, the E-insulin comprises, consists essentially of, or consists of the amino acid sequence encoded by SEQ ID NO: 6.
In certain embodiments, the insulin A-chain and the insulin B -chain are covalently linked by a disulfide bond.
In certain embodiments, the insulin A-chain and the insulin B -chain are covalently linked by two disulfide bonds.
In certain embodiments, the E-insulin of the invention further comprises an H10D substitution on the insulin B-chain.
Another aspect of the invention provides a mature E-insulin resulting from cleavage of the E-insulin of the invention described herein, at the first cleavable heterologous peptide and said second cleavable heterologous peptide, wherein said insulin A-chain and said insulin B-chain are covalently linked by two disulfide bonds.
In certain embodiments, the mature E-insulin comprises a first remnant sequence of the first cleavable heterologous peptide, optionally, the first remnant sequence is removed by a carboxypeptidase (such as carboxypeptidase E) in said mature E-insulin.
In certain embodiments, the mature E-insulin does not have any remnant sequence of the first cleavable heterologous peptide after removal of such remnant sequence by a carboxypeptidase (such as carboxypeptidase E).
Another aspect of the invention provides a cleaved insulin C-peptide resulting from cleavage of the E-insulin of the invention at the first cleavable heterologous peptide and the second cleavable heterologous peptide, wherein the cleaved insulin C-peptide comprises a remnant sequence of the second cleavable heterologous peptide; optionally, the second remnant sequence is removed by a carboxypeptidase (such as carboxypeptidase E) in the cleaved insulin C-peptide.
Another aspect of the invention provides a polynucleotide encoding the E-insulin of the invention described herein.
Another aspect of the invention provides a vector comprising the polynucleotide of the invention described herein.
In certain embodiments, the vector comprises a transcriptional regulatory element, such as a promoter and/or enhancer, operably linked to a transcription cassette comprising the polynucleotide of the invention.
In certain embodiments, the enhancer and/or the promoter is a muscle-specific control element.
The term “muscle specific control element” refers to a nucleotide sequence that regulates expression of a coding sequence that is specific for expression in muscle tissue. These control elements include enhancers and/or promoters. Exemplary muscle specific control elements include a MCKH7 promoter, an MCK promoter, and a MCK enhancer.
Other muscle-specific control element include human skeletal actin gene element, cardiac actin gene element, myocyte- specific enhancer binding factor MEF, muscle creatine kinase (MCK), tMCK (truncated MCK), myosin heavy chain (MHC), MHCK7 (a hybrid version of MHC and MCK), C5-12 (synthetic promoter), murine creatine kinase enhancer element, skeletal fast-twitch troponin C gene element, slow-twitch cardiac troponin C gene element, slow-twitch troponin I gene element, hypoxia- inducible nuclear factors, steroid- inducible element or glucocorticoid response element (GRE).
In certain embodiments, the promoter comprises: (1) a constitutively active eukaryotic promoter, (2) a muscle-specific promoter, and/or (3) a synthetic promoter.
In certain embodiments, the vector comprises two promoters.
In certain embodiments, the vector comprises: (1) a first transcription cassette comprising the polynucleotide of the invention operably linked to a first promoter (e.g., a muscle- specific promoter such as MCK, or a constitutive promoter such as CBA or CAG); and, (2) a second transcription cassette comprising the polynucleotide of the invention operably linked to a second promoter, such as a synthetic promoter; wherein the polynucleotides of the invention in the first and the second transcription cassettes are independently selected from the E-insulin of the invention described herein.
In certain embodiments, the muscle-specific promoter is MHCK7, CK8e, tMCK, (human) skeletal a- actin (HSA) promoter (including full length or shortedn HAS promoter, and chimeric HSA/CMV promoter consisting of a fragment of the HSA promoter and the CMV promoter), muscle creatine kinase (MCK/CKM) promoter or derivative thereof (including CK6, MHCK7, dMCK, tMCK, CK8 and CK8e), desmin gene promoter, human a- myosin heavy chain gene (aMHC) promoter, myosin light-chain promoter (MLC2v), cardiac troponin T promoter (cTnT), a chimeric promoter comprising the CMV-IE enhancer ligated to the 1.5-kbp fragment of the rat promoter MLC, and the AUSEx3 promoter developed from the human troponin I (TNNI1) gene. See Skopenkova el al., Muscle-Specific Promoters for Gene Therapy, Acta Naturae. 13(1): 47-58, 2021 (incorporated herein by reference).
In certain embodiments, the constitutive promoter is: CAG, CB, CB6, respiratory syncytial virus (RSV) promoter, cytomegalovirus (CMV) promoter, or elongation factor la (EFla) promoter.
In certain embodiments, the promoter is a synthetic promoter. Synthetic promoter is a groundbreaking approach in promoter design. This strategy enables one to engineer promoters with defined properties, such as size and the expression profile of the transgene. The development of synthetic promoters relies on computational algorithms, which are used to identify regulatory sequences and TFBSs within the genome, as well as to predict the promoter regions. For example, the binding sites for myogenic TFs are usually shorter than 10 bp, which allows one to create a library of constructs with different combinations of muscle- specific TFBSs.
In certain embodiments, the synthetic promoter is the SPc5-12 promoter (Li et al., Nat. Biotechnol. 17(3):241-245, 1999). The SPc5-12 promoter consists of a combination of four muscle-specific TFBSs (TEF1, SRE, MEF1, and MEF2) and the core promoter (a fragment of the promoter of the chicken skeletal muscle a-actin gene). Its activity in muscle fibers is reportedly six-fold higher than that of the CMV promoter. Further, in vivo experiments confirmed that the SPc5-12 promoter is inactive in undifferentiated myoblasts and in various nonmuscle cell lines.
In certain embodiments, the synthetic promoter is the SP-301 promoter (Liu et al., Plasmid. 106:102441, 2019). The SP-301 promoter is a combination of muscle- specific TFBSs, viral elements, and conserved cis-regulatory elements ligated in forward and reverse orientation. The SP-301 promoter is 6.6 times more active than the CMV promoter 2 days after intramuscular delivery of the construct in mice and remained active for at least a month. The tissue specificity of the SP-301 promoter was confirmed in transgenic mice.
In certain embodiments, the synthetic promoter is the MH promoter. The MH promoter consists of the human desmin gene enhancer linked to the enhancer, the core promoter, and the first intron of the mouse Ckm gene. The MH promoter ensured the highest expression level in the muscle cell culture, being superior to the desmin and CMV promoters. AAV2/9 carrying a reporter gene delivered intravenously in mice under the control of the MH promoter has higher reporter activity in the cardiac and skeletal muscles than that of the desmin and CMV promoters. Further, the MH promoter does not induce transgene expression in the liver.
In certain embodiments, the synthetic promoter is the Sk-CRM4/Des promoter, which is the regulatory module Sk-CRM4 ligated to the desmin promoter and the MVM intron. Six weeks after systemic delivery using AAV9, the Sk-CRM4 chimeric promoter enhanced the activity of the desmin promoter by 200-400 times in different skeletal muscles, the diaphragm, and the heart, while remaining inactive in non-target tissues. Moreover, the SkCRM4/Des promoter attained a 25-173 times higher expression in different muscles as compared to the CMV promoter and also outperformed the Sk-CRM4/ SPc5-12 and SPc5-12 promoters. Therefore, the computationally designed Sk-CRM4/Des chimeric promoter demonstrated improved muscle- specific performance as compared to the other promoters commonly used for muscle gene therapy.
In certain embodiments, the transcription cassette(s) further encodes a 5’-UTR region, a 3’-UTR region, and/or a polyA signal operably linked to the polynucleotide of the invention.
In certain embodiments, the 5’-UTR region comprises an intron. Expression of the target gene such as E-insulin can be enhanced due to the presence of an intron in the vector. The intron is typically positioned between the promoter and the coding region. While not wishing to be bound by any particular theory, the presence of the intron is believed to increase RNA stability in the nucleus due to the incorporation of mRNA into the spliceosome and promotes efficient export of spliced mRNA from the nucleus to the cytoplasm.
In certain embodiments, the introns contains regulatory sequences that affect tissue specificity and the expression level of the target gene. In certain embodiments, the intron is from the Ckm gene. In certain embodiments, the intron is the MVM intron.
In certain embodiments, the 3’-UTR comprises a (600-bp) post-transcriptional regulatory element of the woodchuck hepatitis virus (WPRE) which can lead to an enhancement of transgene expression in muscles. WPRE is believed to promote mRNA export from the nucleus and prevents post-translational gene silencing.
In certain embodiments, the AAV vector of the invention further comprises an miRNA detargeting sequence that suppresses expression of the target gene in a non-target tissue, such as liver or neuronal tissues. For this purpose, the binding sites for certain microRNA that are present only in the non-target organs are added to the 3’-UTR of the expression cassette (e.g., miRNA detargeting sites). If transgenic mRNA is expressed in a non-target organ, microRNA binds to such complementary detargeting sites on the transgene and initiates its degradation.
In certain embodiments, the vector is an AAV (adeno-associated viral) vector further comprising a 5’ ITR and/or a 3’ ITR.
As used herein, the term “AAV” is a standard abbreviation for adeno-associated virus. Adeno-associated virus is a single- stranded DNA parvovirus that grows only in cells in which certain functions are provided by a co-infecting helper virus. Numerous serotypes of AAV have been characterized. General information and reviews of AAV can be found in, for example, Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169- 228, and Berns, 1990, Virology, pp. 1743-1764, Raven Press, (New York, incorporated herein by reference). However, it is fully expected that these same principles will be applicable to additional AAV serotypes since it is well known that the various serotypes are quite closely related, both structurally and functionally, even at the genetic level. (See, for example, Blacklowe, 1988, pp. 165-174 of Parvoviruses and Human Disease, J. R. Pattison, ed.; and Rose, Comprehensive Virology 3:1-61 (1974)). For example, all AAV serotypes apparently exhibit very similar replication properties mediated by homologous rep genes; and all bear three related capsid proteins such as those expressed in AAV2. The degree of relatedness is further suggested by heteroduplex analysis which reveals extensive cross-hybridization between serotypes along the length of the genome; and the presence of analogous self-annealing segments at the termini that correspond to "inverted terminal repeat sequences" (ITRs). The similar infectivity patterns also suggest that the replication functions in each serotype are under similar regulatory control.
An “AAV vector” or “AAV vector genome (vg)” as used herein refers to a vector comprising one or more polynucleotides of interest (or transgenes) that are flanked by AAV terminal repeat sequences (ITRs). Such AAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that has been transfected with a vector encoding and expressing rep and cap gene products.
Another aspect of the invention provides an AAV viral particle comprising the AAV vector of the invention, encapsidated within a capsid.
An “AAV virion” or “AAV viral particle” refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. The particle comprises a heterologous polynucleotide (i.e., a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell). Thus, production of AAV vector particle necessarily includes production of AAV vector, as such a vector is contained within an AAV vector particle.
In certain embodiments, the capsid has a serotype with muscle tropism, such as tropism for skeletal muscle, smooth muscle, or cardiac muscle.
In certain embodiments, the capsid has the serotype of AAV1, AAV2, AAV6, AAV7, AAV8, AAV9, AAV-DJ/8, AAV-RhlO, AAV-retro, AAV-PHP.B, AAV-PHP.eB, or AAV- PHP.S, or a genetically engineered AAV Capsid.
Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692 (incorporated herein by reference). Other types of rAAV variants, for example rAAV with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy 22(11): 1900-1909, 2014 (incorporated herein by reference).
Another aspect of the invention provides a method of delivering an engineered insulin polypeptide to a muscle cell, the method comprising contacting the muscle cell with the AAV viral particle of the invention.
In certain embodiments, the muscle cell is in an animal, such as a human or a nonhuman mammal.
In certain embodiments, the animal has Type 1 or Type 2 diabetes, or hyperglycemia.
Another aspect of the invention provides a method of treating a subject in need of treatment for a disease treatable by insulin, the method comprising administering to the subject a therapeutically effective amount of the AAV viral particle of the invention.
In certain embodiments, the AAV viral particle is administered systemically, such as parental administration by injection, infusion or implantation.
In certain embodiments, the AAV viral particle is administered by intramuscular injection or intravenous injection.
In certain embodiments, the AAV viral particle is delivered intramuscularly.
In certain embodiments, the subject has Type 1 diabetes.
In certain embodiments, the subject has Type 2 diabetes.
In certain embodiments, the subject has hyperglycemia.
It should be understood that any one embodiment of any one of the aspects of the invention above, including specific embodiments described only in one section of the application, can be combined with one or more additional embodiments.
Another aspect of the invention provides a composition, such as a pharmaceutical composition, comprising the E-insulin polypeptide of the invention, the polynucleotide encoding the E-insulin polypeptide of the invention, the vector of the invention comprising
the polynucleotide of the invention, the AAV vector genome of the invention comprising the polynucleotide of the invention, and/or the AAV viral particle of the invention encapsidating the AAV vector genome of the invention in a suitable capsid, such as a capsid with muscle tropism.
In certain embodiments, the composition of the invention is formulated for intramuscular injection or intravenous injection. In certain embodiments, the composition of the invention is formulated for systemic administration, such as parental administration by injection, infusion or implantation.
In certain embodiments, in any of the provided formulations or compositions, the buffer agent comprises one or more of tris, tricine, Bis-tricine, HEPES, MOPS, TES, TAPS, PIPES, and CAPS. For example, the buffer agent may comprise tris with pH 8.0 at concentration of about 5 mM to about 40 mM, or the buffer agent may comprise the tris with pH 8.0 at about 20 mM.
In certain embodiments, in any of the subject formulations or compositions, the ionic strength agent comprises one or more of potassium chloride (KC1), potassium acetate, potassium sulfate, ammonium sulfate, ammonium chloride (NH4CI), ammonium acetate, magnesium chloride (MgCh), magnesium acetate, magnesium sulfate, manganese chloride (MnCh), manganese acetate, manganese sulfate, sodium chloride (NaCl), sodium acetate, lithium chloride (LiCl), and lithium acetate.
For example, the ionic strength agent comprises MgCh at a concentration of about 0.2 mM to about 4 mM; or the ionic strength agent comprises NaCl at a concentration of about 50 mM to about 500 mM; or the ionic strength agent comprises MgCh at a concentration of about 0.2 mM to about 4 mM and NaCl at a concentration of about 50 mM to about 500 mM, or the ionic strength agent comprises MgCh at a concentration of about 1 mM and NaCl at a concentration of about 200 mM.
In certain embodiments, in any of the provided formulations or compositions, the surfactant comprises one or more of a sulfonate, a sulfate, a phosphonate, a phosphate, a Poloxamer, and a cationic surfactant. For example, the Poloxamer comprises one or more of Poloxamer 124, Poloxamer 181, Poloxamer 184, Poloxamer 188, Poloxamer 237, Poloxamer 331, Poloxamer 338, and Poloxamer 407. The Poloxamer may be at a concentration of about 0.00001% to about 1%. An exemplary surfactant is Poloxamer 188 at a concentration of about 0.001%.
2. AAV
Recombinant AAV genomes of the invention comprise a polynucleotide or nucleic acid molecule of the invention, and one or more AAV ITRs flanking the polynucleotide or nucleic acid molecule. AAV DNA in the rAAV genomes may be from any AAV serotype for which a recombinant virus can be derived including, but not limited to, AAV serotypes AAV1, AAV2, AAV6, AAV7, AAV8, AAV9, AAV-DJ/8, AAV-RhlO, AAV-retro, AAV- PHP.B, AAV-PHP.eB, AAV-PHP.S, AAV-rh.10 or AAV-rh.74, or a genetically engineered AAV Capsid. In certain embodiments, the AAV viral particle has a serotype with muscle tropism, either exclusively, or preferentially.
Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692. Other types of rAAV variants, for example rAAV with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11): 1900-1909 (2014). The nucleotide sequences of the genomes of various AAV serotypes are known in the art.
In certain embodiments, to promote skeletal muscle specific expression, AAV-1, AAV-5, AAV-6, AAV-rh74, AAV-8 or AAV-9, for example, may be used.
In a related aspect, the invention also provides DNA plasmids comprising rAAV vector genomes of the invention. The DNA plasmids can be transferred to cells permissible for infection with a helper virus of AAV (e.g., adenovirus, El- deleted adenovirus or herpes virus) for assembly of the rAAV genome into infectious viral particles.
Techniques to produce rAAV particles, in which an AAV genome to be packaged, rep and cap genes, and helper virus functions are provided to a cell are standard in the art, and is commonly known as the so-called the “triple transfection” method, even though the method of introduction may not necessarily be the traditional means for plasmid transfection.
Production of rAAV generally requires that the following components be present within a single cell (denoted herein as a packaging cell): a rAAV genome, AAV rep and cap genes separate from (i.e., not in) the rAAV genome, and helper virus functions.
The AAV rep and cap genes may be from any AAV serotype for which recombinant virus can be derived and may be from a different AAV serotype than the rAAV genome ITRs, including, but not limited to, AAV serotypes AAV1, AAV2, AAV6, AAV7, AAV8, AAV9, AAV-DJ/8, AAV-RhlO, AAV-retro, AAV-PHP.B, AAV-PHP.eB, AAV-PHP.S, AAV-rh.10 or AAV-rh.74, or a genetically engineered AAV Capsid. Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692 which is incorporated by reference herein in its entirety.
A method of generating a packaging cell is to create a cell line that stably expresses all the necessary components for AAV particle production. For example, a plasmid (or multiple plasmids) comprising a rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes separate from the rAAV genome, and a selectable marker, such as a neomycin resistance gene, are integrated into the genome of a cell. AAV genomes have been introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al., Proc. Natl. Acad. S6. USA 79:2077-2081, 1982), addition of synthetic linkers containing restriction endonuclease cleavage sites (Laughlin et al., Gene, 23:65-73, 1983) or by direct, blunt-end ligation (Senapathy & Carter, J. Biol. Chem, 259:4661-4666, 1983). The packaging cell line is then infected with a helper virus such as adenovirus. The advantages of this method are that the cells are selectable and are suitable for large-scale production of rAAV. Other examples of suitable methods employ adenovirus or baculovirus rather than plasmids to introduce rAAV genomes and/or rep and cap genes into packaging cells.
General principles of rAAV production are reviewed in, for example, Carter, 1992, Current Opinions in Biotechnology, 1533-539; and Muzyczka, 1992, Curr. Topics in Microbial, and Immunol., 158:97-129). Various approaches are described in Ratschin et al., Mol. Cell. Biol. 4:2072 (1984); Hermonat et al., Proc. Natl. Acad. Sci. USA, 81:6466 (1984); Tratschin et al., Mol. Cell. Biol. 5:3251 (1985); McLaughlin et al., J. Virol., 62:1963 (1988); and Lebkowski et al., 1988 Mol. Cell. Biol., 7:349 (1988). Samulski et al. (1989, J. Virol., 63:3822-3828); U.S. Patent No. 5,173,414; WO 95/13365 and corresponding U.S. Patent No. 5,658.776 ; WO 95/13392; WO 96/17947; PCT/US98/18600; WO 97/09441 (PCT/US96/14423); WO 97/08298 (PCT/US96/13872); WO 97/21825 (PCT/US96/20777); WO 97/06243 (PCT/FR96/01064); WO 99/11764; Perrin et al. (1995) Vaccine 13:1244- 1250; Paul et al. (1993) Human Gene Therapy 4:609-615; Clark et al. (1996) Gene Therapy 3:1124-1132; U.S. Patent. No. 5,786,211; U.S. Patent No. 5,871,982; and U.S. Patent. No. 6,258,595. The foregoing documents are hereby incorporated by reference in their entirety herein, with particular emphasis on those sections of the documents relating to rAAV production.
The invention thus provides packaging cells that produce infectious rAAV. In one embodiment packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells and PerC.6 cells (a cognate 293 line). In another embodiment, packaging cells are cells that are not transformed cancer cells, such as low passage 293 cells (human fetal kidney cells transformed with El of adenovirus), MRC-5 cells (human fetal fibroblasts), WL38 cells
(human fetal fibroblasts), Vero cells (monkey kidney cells) and FRhL-2 cells (rhesus fetal lung cells).
Recombinant AAV (i.e., infectious encapsidated rAAV particles) of the invention comprise a rAAV genome.
The rAAV may be purified by methods standard in the art such as by column chromatography or cesium chloride gradients. Methods for purifying rAAV vectors from helper virus are known in the art and include methods disclosed in, for example, Clark et al., Hum. Gene Ther., 10(6): 1031-1039 (1999); Schenpp and Clark, Methods Mol. Med., 69427- 443 (2002); U.S. Patent No. 6,566,118 and WO 98/09657.
3. Composition and Pharmaceutical Composition
Another aspect of the invention provides compositions comprising the E-insulin of the invention, the polynucleotide encoding the E-insulin of the invention, and/or the vector comprising the polynucleotide of the invention.
In certain embodiments, the vector is an rAAV of the present invention.
Compositions described herein comprise rAAV in a pharmaceutically acceptable carrier. The compositions may also comprise other ingredients such as diluents and adjuvants.
Acceptable carriers, diluents and adjuvants are nontoxic to recipients and are preferably inert at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, pluronics or polyethylene glycol (PEG).
Titers of rAAV to be administered in methods of the invention will vary depending, for example, on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be determined by methods standard in the art.
Exemplary titers of rAAV may range from about 1 x 106, about 1 x 107, about 1 x 108, about 1 x 109, about 1 x IO10, about 1 x 1011, about 1 x 1012, about 1 x 1013 to about 1 x 1014 or more DNase resistant particles (DRP) per ml.
Dosages may also be expressed in units of viral genomes (vg). The titers of rAAV may be determined by the supercoiled plasmid quantitation standard or the linearized plasmid quantitation standard.
In certain embodiment, the disclosure provides methods of measuring the titer of an AAV vector, comprising tittering the AAV vector with PCR with a first primer and a second primer. In another embodiment, methods of measuring the titer of an AAV vector, comprising tittering the AAV vector with a probe.
Methods of transducing a target cell with rAAV, in vivo or in vitro, are contemplated by the invention. The in vivo methods comprise the step of administering an effective dose, or effective multiple doses, of a composition comprising a rAAV of the invention to an animal (including a human being) in need thereof. If the dose is administered prior to development of a disorder/disease, the administration is prophylactic. If the dose is administered after the development of a disorder/disease, the administration is therapeutic. In embodiments of the invention, an effective dose is a dose that alleviates (eliminates or reduces) at least one symptom associated with the disorder/disease state being treated, that slows or prevents progression to a disorder/disease state, that slows or prevents progression of a disorder/disease state, that diminishes the extent of disease, that results in remission (partial or total) of disease, and/or that prolongs survival. An example of a disease contemplated for prevention or treatment with methods of the invention is T1DM, T2DM, or hyperglycemia.
Pharmaceutical compositions of the invention can be prepared as injectable formulations or as topical formulations to be delivered to the muscles by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and can be used in the practice of the invention.
The rAAV can be used with any pharmaceutically acceptable carrier for ease of administration and handling. Thus, in another aspect, the application is directed to a formulation that comprises an rAAV that comprises a suitable AAV capsid with muscle tropism, such as AAV9, a buffer agent, an ionic strength agent, and a surfactant.
In one embodiment, the rAAV is at a concentration of 1.0 x 1012 vg/mL to about 1.0 x 1016 vg/mL, or about 1.0 x 1012 vg/mL to about 5.0 x 1014 vg/mL.
In another embodiment, the rAAV is at a concentration of about 5.0 x 1012 vg/mL to about 1.0 x 1014 vg/mL based on a supercoiled plasmid as the quantitation standard.
In another embodiment, the rAAV is at a concentration of about 5.0 x 1012 vg/mL to about 1.0 x 1014 vg/mL based on a linearized plasmid as the quantitation standard.
In another embodiment, the rAAV is at a concentration of about 2.0 x 1013 vg/mL based on a supercoiled plasmid as the quantitation standard.
In one embodiment, the concentration of rAAV in the composition or formulation is from 1.0 x 1013 vg/mL to 2.0 x 1014 vg/mL based on a supercoiled plasmid as the quantitation standard.
In another embodiment, the concentration is 2.0 x 1013 vg/mL, 4.0 x 1013 vg/mL, or 5.0 x 1013 vg/mL based on a supercoiled plasmid as the quantitation standard.
In one embodiment, the buffer agent comprises one or more of tris, tricine, Bis- tricine, HEPES, MOPS, TES, TAPS, PIPES, and CAPS.
In another embodiment, the buffer agent comprises tris with pH 8.0 at concentration of about 5 mM to about 40 M.
In one embodiment, the buffer agent comprises tris with pH 8.0 at about 20 mM.
In one embodiment, the ionic strength agent comprises one of more of potassium chloride (KC1), potassium acetate, potassium sulfate, ammonium sulfate, ammonium chloride (NH4CI), ammonium acetate, magnesium chloride (MgCh), magnesium acetate, magnesium sulfate, manganese chloride (MnCh), manganese acetate, manganese sulfate, sodium chloride (NaCl), sodium acetate, lithium chloride (LiCl), and lithium acetate.
In one embodiment, the ionic strength agent comprises MgCh at a concentration of about 0.2 mM to about 4 mM. In another embodiment, the ionic strength agent comprises NaCl at a concentration of about 50 mM to about 500 mM. In another embodiment, the ionic strength agent comprises MgCh at a concentration of about 0.2 mM to about 4 mM and NaCl at a concentration of about 50 mM to about 500 mM. In another embodiment, the ionic strength agent comprises MgCh at a concentration of about 1 mM and NaCl at a concentration of about 200 mM.
In one embodiment, the surfactant comprises one or more of a sulfonate, a sulfate, a phosphonate, a phosphate, a Poloxamer, and a cationic surfactant.
In one embodiment, the Poloxamer comprises one or more of Poloxamer 124, Poloxamer 181, Poloxamer 184, Poloxamer 188, Poloxamer 237, Poloxamer 331, Poloxamer 338, and Poloxamer 407.
In one embodiment, the surfactant comprises the Poloxamer at a concentration of about 0.00001% to about 1%.
In another embodiment, the surfactant comprises Poloxamer 188 at a concentration of about 0.001%.
For purposes of intramuscular injection, solutions in an adjuvant such as sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions. Such aqueous solutions can be buffered, if desired, and the liquid diluent first rendered isotonic with saline or glucose. Solutions of rAAV as a free acid (DNA contains acidic phosphate groups) or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxpropylcellulose. A dispersion of rAAV can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils.
Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating actions of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of a dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, phenol, chlorobutanol, sorbic acid, thimerosal and the like. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating rAAV in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying technique that yield a powder of the active ingredient plus any additional desired ingredient from the previously sterile-filtered solution thereof.
4. Administration
Administration of an effective dose of the compositions may be by routes standard in the art including, but not limited to, intramuscular, parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or vaginal. Route(s) of administration and serotype(s) of AAV components of the rAAV (in particular, the AAV ITRs and capsid protein) of the invention may be chosen and/or matched by those skilled in the art taking into account the infection and/or disease state being treated and the target cells/tissue(s) that are to express the E-insulin.
The invention provides for local administration and systemic administration of an effective dose of rAAV and compositions of the invention. For example, systemic administration is administration into the circulatory system so that the entire body is affected. Systemic administration includes enteral administration such as absorption through the gastrointestinal tract and parental administration through injection, infusion or implantation.
For example, administration of rAAV of the present invention may be accomplished by using any physical method that will transport the rAAV recombinant vector into the target tissue of an animal. Administration according to the invention includes, but is not limited to, injection into muscle, the bloodstream and/or directly into the liver. Simply resuspending a rAAV in phosphate buffered saline has been demonstrated to be sufficient to provide a vehicle useful for muscle tissue expression, and there are no known restrictions on the carriers or other components that can be co-administered with the rAAV (although compositions that degrade DNA should be avoided in the normal manner with rAAV). Capsid proteins of a rAAV may be modified so that the rAAV is targeted to a particular
target tissue of interest such as muscle. See, for example, WO 02/053703, the disclosure of which is incorporated by reference herein.
Transduction with rAAV may also be carried out in vitro. In one embodiment, desired target muscle cells are removed from the subject, transduced with rAAV and reintroduced into the subject. Alternatively, syngeneic or xenogeneic muscle cells can be used where those cells will not generate an inappropriate immune response in the subject.
Suitable methods for the transduction and reintroduction of transduced cells into a subject are known in the art. In one embodiment, cells can be transduced in vitro by combining rAAV with muscle cells, e.g., in appropriate media, and screening for those cells harboring the DNA of interest using conventional techniques such as Southern blots and/or PCR, or by using selectable markers. Transduced cells can then be formulated into pharmaceutical compositions, and the composition introduced into the subject by various techniques, such as by intramuscular, intravenous, subcutaneous and intraperitoneal injection, or by injection into smooth and cardiac muscle, using e.g., a catheter.
Transduction of cells with rAAV of the invention results in sustained expression of E- insulin.
The present invention thus provides methods of administering/delivering rAAV which express E-insulin to a mammalian subject, preferably a human being. These methods include transducing tissues (including, but not limited to, tissues such as muscle, organs such as liver and brain, and glands such as salivary glands) with one or more rAAV of the present invention. Transduction may be carried out with gene cassettes comprising tissue specific control elements.
For example, one embodiment of the invention provides methods of transducing muscle cells and muscle tissues directed by muscle specific control elements, including, but not limited to, those derived from the actin and myosin gene families, such as from the myoD gene family [See Weintraub et al., Science, 251: 761-766 (1991)], the myocyte- specific enhancer binding factor MEF-2 [Cseijesi and Olson, Mol Cell Biol 11: 4854-4862 (1991)], control elements derived from the human skeletal actin gene [Muscat et al., Mol Cell Biol, 7: 4089-4099 (1987)], the cardiac actin gene, muscle creatine kinase sequence elements [See Johnson et al., Mol Cell Biol, 9:3393-3399 (1989)] and the murine creatine kinase enhancer (mCK) element, control elements derived from the skeletal fast-twitch troponin C gene, the slow-twitch cardiac troponin C gene and the slow-twitch troponin I gene: hypoxia-inducible nuclear factors (Semenza et al., Proc Natl Acad Sci USA, 88: 5680-5684 (1991)), steroid-
inducible elements and promoters including the glucocorticoid response element (GRE) (See Mader and White, Proc. Natl. Acad. Sci. USA 90: 5603-5607 (1993)), and other control elements.
Muscle tissue is an attractive target for in vivo DNA delivery, because it is not a vital organ and is easy to access. The invention contemplates sustained expression of E-insulin mRNAs from transduced myofibers.
By “muscle cell” or “muscle tissue” is meant a cell or group of cells derived from muscle of any kind (for example, skeletal muscle and smooth muscle, e.g. from the digestive tract, urinary bladder, blood vessels or cardiac tissue). Such muscle cells may be differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes and cardiomyoblasts.
The term “transduction” is used to refer to the administration/delivery of a polynucleotide of interest (e.g., a polynucleotide sequence encoding E-insulin) to a recipient cell either in vivo or in vitro, via a replication-deficient rAAV described resulting in expression of E-insulin by the recipient cell.
Thus, also described herein are methods of administering an effective dose (or doses, administered essentially simultaneously or doses given at intervals) of rAAV that encode E- insulin to a mammalian subject in need thereof.
5. Combination Therapy
Combination therapies are also contemplated by the invention. Combination as used herein includes both simultaneous treatment or sequential treatments. Combinations of methods of the invention with standard medical treatments are specifically contemplated, as are combinations with novel therapies.
In this regard, the combinations include administering to a subject one or more treatment suitable for treatment by insulin, before, simultaneous, or after the administration of an rAAV of the invention to a subject in need thereof.
In certain embodiments, the treatment suitable for treatment by insulin comprises medical nutrition therapy (MNT), a process by which the dietary plan of the subject or patient is tailored based on medical, lifestyle, and personal factors.
In certain embodiments, the treatment suitable for treatment by insulin comprises weight reduction treatment, e.g., for overweight (BMI >25 to 29.9 kg/m2) or obese (BMI >30
kg/m2) patients with type 2 diabetes. The weight reduction treatment may comprise reducing caloric intake, increasing physical activity, and/or behavior modification to achieve weight loss.
In certain embodiments, the treatment suitable for treatment by insulin comprises diet or diet control.
In certain embodiments, the treatment suitable for treatment by insulin comprises exercise, such as aerobic exercise that may include 30 to 60 minutes of moderate-intensity aerobic activity (40 to 60 percent VO2 max) on most days of the week (e.g., at least 150 minutes of moderate-intensity aerobic exercise per week, spread over at least three days per week, with no more than two consecutive days without exercise); and/or resistance training (e.g., exercise with free weights or weight machines at least twice per week).
In certain embodiments, the treatment suitable for treatment by insulin comprises a pharmacological intervention that may comprise one or more of: metformin (e.g., 500 mg once daily with the evening meal and, if tolerated, add a second 500 mg dose with breakfast), GLP-1 receptor agonists (such as liraglutide, semaglutide, dulaglutide), SGLT2 inhibitor (such as empagliflozin, canagliflozin, and dapagliflozin), sulfonylurea (such as glipizide or glimepiride), DPP-4 inhibitor, repaglinide, or pioglitazone.
With the general parameters of the invention described above, additional aspects or features of the invention are provided in further details below.
All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
The invention is further described in the following Examples, which do not limit the scope of the invention described in the claims.
EXAMPLES
Example 1
One exemplary (non-limiting) engineered insulin (E-insulin) of the invention, including a signal peptide, was constructed, with the following polynucleotide and polypeptide sequences:
Engineered Insulin (E-Insulin) polynucleotide sequence:
ATGGACCCCCCACGCCCAGCATTGCTGGCCCTCCTTGCATTGCCCGCTTTGCTGTTGCTGCT TCTTGCAGGTGCGCGGGCGTTTGTGAACCAACACCTGTGCGGCTCACACCTGGTGGAAGCTC TCTACCTAGTGTGCGGGGAACGAGGCTTCTTCTACACACCCAAGACCCGCCGGAGAGGCGTG TTCAGAAGAGAGGCAGAGGACCTGCAGGTGGGGCAGGTGGAGCTGGGCGGGGGCCCTGGTGC AGGCAGCCTGCAGCCCTTGGCCCTGGAGGGGTCCCTGCAGAAGCGTCGGGGCGTCTTCCGCC GCGGCATTGTGGAACAATGCTGTACCAGCATCTGCTCCCTCTACCAGCTGGAGAACTACTGC
AACTAG ( SEQ ID NO : 6 )
Engineered Insulin (E-Insulin) polypeptide sequence:
MDPPRPALLALLALPALLLLLLAGARAFVNQHLCGSHLVEALYLVCGERGFFYTPKTRRRGV FRREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKRRGVFRRGIVEQCCTSICSLYQLENYC N ( SEQ ID NO : 7 )
Parts of the E-insulin sequence:
1. Signal peptide: MDPPRPALLALLALPALLLLLLAGARA ( SEQ ID NO : 1 )
2 . B-chain : FVNQHLCGSHLVEALYLVCGERGFFYTPKTRR ( SEQ ID NO : 2 )
3 . 1st and 2nd Heterologous Sequences : RGVFRR ( SEQ ID NO : 3 )
4 . C peptide : EAEDLQVGQVELGGGPGAGSLQPLALEGSLQKR ( SEQ ID
NO : 4 )
5 . A-chain : GIVEQCCTSICSLYQLENYCN ( SEQ ID NO : 5 )
Note that the terminal one or two basic residue(s) in the B-chain and the C-peptide could be removed by enzymes such as carboxy peptidase after cleavage, and may or may not be present in the mature B-chain or C-peptide.
In this specific example, the sequence of RGVFRR (SEQ ID NO: 3) was inserted at the juncture of the natural human insulin B-chain and C-peptide as the first heterologous peptide, and again at the juncture of the natural human insulin C-peptide and A-chain as the second heterologous peptide, though it is not required for the two heterologous peptides to be the same.
For comparison, the full length human insulin polynucleotide and polypeptide sequences are provided below.
Full-length human insulin (Insulin - FL) polynucleotide sequence:
ATGGACCCCCCACGCCCAGCATTGCTGGCCCTCCTTGCATTGCCCGCTTTGCTGTTGCTGCT TCTTGCAGGTGCGCGGGCGTTTGTGAACCAACACCTGTGCGGCTCACACCTGGTGGAAGCTC TCTACCTAGTGTGCGGGGAACGAGGCTTCTTCTACACACCCAAGACCCGCCGGGAGGCAGAG GACCTGCAGGTGGGGCAGGTGGAGCTGGGCGGGGGCCCTGGTGCAGGCAGCCTGCAGCCCTT GGCCCTGGAGGGGTCCCTGCAGAAGCGTGGCATTGTGGAACAATGCTGTACCAGCATCTGCT CCCTCTACCAGCTGGAGAACTACTGCAACTAG ( SEQ ID NO : 8 )
Full-length human insulin (Insulin - FL) polypeptide sequence:
MDPPRPALLALLALPALLLLLLAGARAFVNQHLCGSHLVEALYLVCGERGFFYTPKTRREAE DLQVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCN ( SEQ ID NO : 9 )
The polynucleotide of SEQ ID NO: 6 was first inserted into an expression vector to show that E-insulin can be expressed in vitro.
As shown in FIG. 4, upon restriction enzyme digestion, the E-insulin insert was released from the plasmid backbone, as were resolved on electrophoresis. A similarly digested control plasmid, with the wild-type full-length (FL) insulin coding sequence, released the slightly smaller FL insulin coding sequence fragment on the same gel.
FIG. 5 shows that the E-insulin can be secreted and further be processed to mature forms, the same way the wild-type FL insulin can. Indeed, a majority of the E-insulin appeared to be processed to the mature form, which has a smaller molecular weight, and comigrates with commercial insulin product Novolin. Meanwhile, FL insulin has a significant portion remain unprocessed to the mature form, and remains full length (including the C- peptide).
As a further evidence that the E-insulin was fully processed, Western blotting against the C-peptide, which was supposed to be released upon protease digestion to produce the mature insulin, showed that the C-peptide was indeed released in the E-insulin sample (FIG. 6), to a much greater extent than that for the wild-type full length (FL) insulin.
FIG. 7 shows that the secreted E-insulin was capable of being a potent inducer in muscle cells (myoblasts) by promoting their differentiation into myotubes. When the coding sequence of E-insulin was introduced into muscle cells, immunoflurescent (IF) staining of myosin heavy chain - a myotube differentiation marker - showed strong signal in the E- insulin panel (FIG. 7, upper right hand panel), while only weak signal was observed in the control FL insulin panel (FIG. 7, upper left hand panel), even though both samples contained equivalent amount of cells as evidenced by DAPI staining (FIG. 7, lower left and right panels).
The polynucleotide of SEQ ID NO: 6 is then inserted into an AAV viral vector, under the control of one of the promoters of the invention, such as a constitutively active eukaryotic promoter, a muscle-specific promoter (such as a CK8 promoter), and/or a synthetic promoter (such as CAG, CBA, or derivative thereof).
Such transcription unit may optionally further comprise a 5’ UTR region, a heterologous intron to enhance expression of the insulin, a 3’ UTR region, and/or a polyA tail.
The AAV vector genome encompassing such a transcription unit is flanked by at least one functional ITR, such as a 5’ ITR and/or a 3’ ITR from AAV2.
The AAV vector genome can be encapsidated in any AAV capsid with preferential tropism for muscle tissues, such as skeletal muscle, smooth muscle (e.g., diaphragm), and/or cardiac muscle. Exemplary suitable AAV capsids include AAV1, AAV2, AAV6, AAV7, AAV8, AAV9, AAV-DJ/8, AAV-RhlO, AAV-retro, AAV-PHP.B, AAV-PHP.eB, or AAV- PHP.S, or a genetically engineered AAV Capsid. For example, AAV9 capsid may be used.
AAV viral particles can be produced using any standard methods, such as the triple transfection method in a host cell (e.g., HEK293) that permits assembling of AAV viral particles from the AAV vector genome described above in one vector, AAV rep and cap genes on a second vector, and helper genes for AAV packaging in a 3rd vector.
The harvested AAV viral particles can then be tittered and administered to an animal or subject in need thereof, such as one having Type 1 diabetes (T1DM), Type 2 diabetes (T2DM), and/or hyperglycemia. The injection can be intramuscular injection (z.m.).
The animal or subject receiving such AAV injection can produce the E-insulin of the invention, that can be secreted into the blood stream from muscle tissues expressing such E- insulin, thereby treating T1DM, T2DM, and/or hyperglycemia.
Example 2
This example demonstrates intramuscular secretion of the subject human insulin from muscle tissue, and the effect of such muscle-secreted insulin in blood glucose reduction.
Specifically, diabetic mice were intramuscularly dosed with an AAV vector harboring a polynucleotide encoding an E-Insulin of the disclosure. Experimental diabetes was induced in 6-week old C57BL6/J mice to develop diabetes, by inducing with Streptozotocin (about 50 mg/kg) in 0.1 M Citrate buffer at pH4.5 daily IP injection for 5 consecutive days. After Streptozotocin treatment, mice were allowed to develop diabetes for two weeks until they reached fasting blood glucose ranging between 300-400 mg/dL.
An AAV9 vector harboring an E-insulin coding sequence was injected intramuscularly in such diabetic mice, with the AAV9 viral particles suspended in about 200 pL of PBS buffer, which total volume was split between muscles of the two hind limbs of each experimental animal. Three AAV doses comprising about 2xl013 (2E13) vg/kg, about 2xl012 (2E12) vg/kg, and about 2xlOn (2E11) vg/kg were used for the study with controls.
After AAV dosing, fasting blood glucose was measured in all animals using a handheld glucometer on a weekly basis. Preliminary analysis of the gathered data showed reduction in fasting blood glucose levels in animals intramuscularly dosed with the AAV9 viral particles harboring the E-Insulin coding sequence (data not shown).
Further detailed analysis of human insulin secretion from muscle tissues into the bloodstream were being conducted.
Claims
1. An engineered insulin polypeptide (E-insulin) engineered from a wild-type insulin sequence in a mammal, comprising:
(a) a first cleavable heterologous peptide, between the insulin B-chain and the insulin C-peptide of the wild-type insulin; and,
(b) a second cleavable heterologous peptide, between the insulin C-peptide and the insulin A-chain of the wild-type insulin; wherein the first and the second cleavable heterologous peptides are both native sequences of the mammal.
2. The E-insulin of claim 1, wherein the mammal is a human.
3. The E-insulin of claim 1 or 2, wherein the first and the second cleavable heterologous peptides are both cleavable by a serine endoprotease expressed in muscle tissues.
4. The E-insulin of any one of claims 1-3, wherein the serine endoprotease is a subtilisin-like endoprotease, such as furin, PACE4, PC4, PC5/6, or LPC/PC8.
5. The E-insulin of any one of claims 1-4, wherein the first cleavable heterologous peptide and the second cleavable heterologous peptide independently comprise a sequence motif Arg-Xaa-Xaa-Arg (wherein Xaa is any amino acid) or Lys/Arg-Arg.
6. The E-insulin of any one of claims 3-5, wherein the serine endoprotease is present or expressed in trans-Golgi network (TGN), such as TGN of muscle tissue / cell.
7. The E-insulin of any one of claims 3-6, wherein the serine endoprotease is Furin.
8. The E-insulin of any one of claims 1-7, wherein the first cleavable heterologous peptide and the second cleavable heterologous peptide both comprise, consist essentially of, or consist of an amino acid sequence independently selected from RGVFRR (SEQ ID NO: 3); RAKR; RKKR; RKYR; RRKR RRRR; RQRR; LSRR; RKRR; RHKR; RERR; RPRR; RARR; RS AR; LRKR; RTRR RTAR; RNTR; RLRR; RWRR; RGKR; RVKR; RHPR; RRGR; RVRR; RDRR; RTGR REAR; RFKR; RYKR; RHAR; RLLR; RVGR; RRAR; HPKR; RFPR; RRTR; RNQR; RSRR RRRK; RSIR; RTPR; RPAR; RNHR; RKTR; RKNR; RLKR; RNRR; RKSR;
RMKR; RNKR RQQR; RIRR; REIR; REKR; RMRR; RPDR; RIVR; RPKR; RLKK; RSKR; RVAR; RGPR RVCR; RAPR; RQIR; RYRR; RKIR; RMIR; RVRK; RRVR; RCQR; RCKR; VRKR; RPVR RHTR; RCRR; RGRR; RISR; RAAR; RLGR; RYPR;
RAGR; RIIR; KSAR; VSRR; RQCR RVKK; RIGR; RTTR; RHRR; WAR; RSHR; RYSR; RCIR; RCYR; RFRK; RYFR; RTMR RHGR; RSPR; RETR; RKFR; RHLR; RKGR; RRKK; RWKR; RVLR; RIKR; VKKR; RFRR RALR; MKKR; RVTR;
NCSR; KRKR; RSSR; RMAR; KRRR; RRPR; TIKR; HLKR; RFER RASR; RRSR; VRRR; KAKR; RDKR; KVKR; RFLR; RLPR; RPPR; RHSR; RSGR; RICR HKKR; RSLR; RLVR; RVPR; RFSR; RTIR; RLTR; RKAR; RAQR; RQMR; RFVR RSNR; RQPR; CVRR; RSYR; IKKR; RHVR; RLAR; RPLR; IGKR; VTKR; RRHR; RRNR VHKR; RCPR; RWPR; SKER; RIKK; RIFR; RVWR; LEGR; LKKR; VFRR; IRKR. The E-insulin of any one of claims 1-8, wherein the insulin B-chain comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 2. The E-insulin of any one of claims 1-9, wherein the insulin C-peptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 4. The E-insulin of any one of claims 1-10, wherein the insulin A-chain comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 5. The E-insulin of any one of claims 1-11, further comprising a signal peptide. The E-insulin of claim 12, wherein the signal peptide comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 1. The E-insulin of any one of claims 1-13, wherein the insulin A-chain and the insulin B-chain are covalently linked by a disulfide bond. The E-insulin of any one of claims 1-14, wherein the insulin A-chain and the insulin B-chain are covalently linked by two disulfide bonds. The E-insulin of any one of claims 1-15, further comprising an H10D substitution on the insulin B-chain. A mature E-insulin resulting from cleavage of the E-insulin of any one of claims 1-16 at said first cleavable heterologous peptide and said second cleavable heterologous peptide, wherein said insulin A-chain and said insulin B-chain are covalently linked by two disulfide bonds. The mature E-insulin of claim 17, comprising a first remnant sequence of the first cleavable heterologous peptide, optionally, the first remnant sequence (and further optionally the last one or two basic residue(s) at the C-terminus of SEQ ID NO: 2) is removed by a carboxypeptidase (such as carboxypeptidase E) in said mature E-
insulin. A cleaved insulin C-peptide resulting from cleavage of the E-insulin of any one of claims 1-16 at said first cleavable heterologous peptide and said second cleavable heterologous peptide, wherein said cleaved insulin C-peptide comprises a remnant sequence of the second cleavable heterologous peptide; optionally, the second remnant sequence (and further optionally the last one or two basic residue(s) at the C- terminus of SEQ ID NO: 4) is removed by a carboxypeptidase (such as carboxypeptidase E) in said cleaved insulin C-peptide. A polynucleotide encoding the E-insulin of any one of claims 1-16. A vector comprising the polynucleotide of claim 20. The vector of claim 21, comprising a promoter operably linked to a transcription cassette comprising the polynucleotide of claim 20. The vector of claim 22, wherein the promoter comprises:
(1) a constitutively active eukaryotic promoter,
(2) a muscle-specific promoter, and/or
(3) a synthetic promoter. The vector of claim 22 or 23, comprising two promoters. The vector of any one of claims 21-24, comprising:
(1) a first transcription cassette comprising the polynucleotide of claim 16 operably linked to a first promoter (e.g., a muscle- specific promoter such as MCK, or a constitutive promoter such as CBA or CAG); and,
(2) a second transcription cassette comprising the polynucleotide of claim 16 operably linked to a second promoter, such as a synthetic promoter; wherein the polynucleotides of claim 20 in the first and the second transcription cassettes are independently selected from the E-insulin of any one of claims 1-16. The vector of any one of claims 22-25, wherein the transcription cassette(s) further encodes a 5’-UTR region, a 3’-UTR region, and/or a polyA signal operably linked to the polynucleotide of claim 20. The vector of any one of claims 21-26, which is an AAV (adeno-associated viral) vector further comprising a 5’ ITR and/or a 3’ ITR.
An AAV viral particle comprising the AAV vector of claim 27, encapsidated within a capsid. The AAV viral particle of claim 28, wherein the capsid has a serotype with muscle tropism, such as tropism for skeletal muscle, smooth muscle, or cardiac muscle. The AAV viral particle of claim 28 or 29, wherein the capsid has the serotype of AAV1, AAV2, AAV6, AAV7, AAV8, AAV9, AAV-DJ/8, AAV-RhlO, AAV-retro, AAV-PHP.B, AAV-PHP.eB, or AAV-PHP.S, or a genetically engineered AAV Capsid. A method of delivering an engineered insulin polypeptide to a muscle cell, the method comprising contacting the muscle cell with the AAV viral particle of claim 29 or 30. The method of claim 31, wherein the muscle cell is in an animal, such as a human or a non-human mammal. The method of claim 32, wherein animal has Type 1 or Type 2 diabetes, or hyperglycemia. A method of treating a subject in need of treatment for a disease treatable by insulin, the method comprising administering to the subject a therapeutically effective amount of the AAV viral particle of any one of claims 27-30. The method of claim 34, wherein the AAV viral particle is delivered intramuscularly. The method of claim 34 or 35, wherein the subject has Type 1 diabetes, Type 2 diabetes, or hyperglycemia. The method of any one of claims 34-36, wherein the subject has hyperglycemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263396861P | 2022-08-10 | 2022-08-10 | |
US63/396,861 | 2022-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024035782A1 true WO2024035782A1 (en) | 2024-02-15 |
Family
ID=87929412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/029845 WO2024035782A1 (en) | 2022-08-10 | 2023-08-09 | Aav-mediated intramuscular delivery of insulin |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024035782A1 (en) |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
WO1995013365A1 (en) | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
WO1995013392A1 (en) | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
WO1997006243A1 (en) | 1995-08-10 | 1997-02-20 | Pasteur Merieux Serums Et Vaccins | Method for purifying viruses by chromatography |
WO1997008298A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
WO1997009441A2 (en) | 1995-09-08 | 1997-03-13 | Genzyme Corporation | Improved aav vectors for gene therapy |
WO1997021825A1 (en) | 1995-12-15 | 1997-06-19 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
WO1998009657A2 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Method for recombinant adeno-associated virus-directed gene therapy |
US5786211A (en) | 1994-06-06 | 1998-07-28 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5871982A (en) | 1994-10-28 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
WO1999011764A2 (en) | 1997-09-05 | 1999-03-11 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
WO2001083692A2 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
WO2005097981A2 (en) * | 2004-04-08 | 2005-10-20 | Crusade Laboratories Limited | Novel herpes simplex viruses |
US9614423B2 (en) | 2012-04-07 | 2017-04-04 | Traugott Weller | Method for producing rotating electrical machines |
US9613872B2 (en) | 2014-09-29 | 2017-04-04 | Kabushiki Kaisha Toshiba | Method of manufacturing semiconductor device |
US9620777B2 (en) | 2013-09-30 | 2017-04-11 | Tdk Corporation | Positive electrode and lithium ion secondary battery using thereof |
US9818600B2 (en) | 2014-03-21 | 2017-11-14 | Hitachi Kokusai Electric, Inc. | Substrate processing apparatus and method of manufacturing semiconductor device |
US20190135889A1 (en) * | 2014-12-01 | 2019-05-09 | Pfenex Inc. | Fusion partners for peptide production |
-
2023
- 2023-08-09 WO PCT/US2023/029845 patent/WO2024035782A1/en unknown
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5658776A (en) | 1993-11-09 | 1997-08-19 | Targeted Genetics Corporation | Generation of high titers of recombinant AAV vectors |
WO1995013365A1 (en) | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
WO1995013392A1 (en) | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
US5786211A (en) | 1994-06-06 | 1998-07-28 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5871982A (en) | 1994-10-28 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
WO1997006243A1 (en) | 1995-08-10 | 1997-02-20 | Pasteur Merieux Serums Et Vaccins | Method for purifying viruses by chromatography |
WO1997008298A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
WO1997009441A2 (en) | 1995-09-08 | 1997-03-13 | Genzyme Corporation | Improved aav vectors for gene therapy |
WO1997021825A1 (en) | 1995-12-15 | 1997-06-19 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
WO1998009657A2 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Method for recombinant adeno-associated virus-directed gene therapy |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
WO1999011764A2 (en) | 1997-09-05 | 1999-03-11 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
WO2001083692A2 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
WO2005097981A2 (en) * | 2004-04-08 | 2005-10-20 | Crusade Laboratories Limited | Novel herpes simplex viruses |
US9614423B2 (en) | 2012-04-07 | 2017-04-04 | Traugott Weller | Method for producing rotating electrical machines |
US9620777B2 (en) | 2013-09-30 | 2017-04-11 | Tdk Corporation | Positive electrode and lithium ion secondary battery using thereof |
US9818600B2 (en) | 2014-03-21 | 2017-11-14 | Hitachi Kokusai Electric, Inc. | Substrate processing apparatus and method of manufacturing semiconductor device |
US9613872B2 (en) | 2014-09-29 | 2017-04-04 | Kabushiki Kaisha Toshiba | Method of manufacturing semiconductor device |
US20190135889A1 (en) * | 2014-12-01 | 2019-05-09 | Pfenex Inc. | Fusion partners for peptide production |
Non-Patent Citations (38)
Title |
---|
A AURICCHIO ET AL: "Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer", GENE THERAPY, vol. 9, no. 14, 1 July 2002 (2002-07-01), pages 963 - 971, XP055041444, ISSN: 0969-7128, DOI: 10.1038/sj.gt.3301746 * |
BERNS: "Virology", 1990, RAVEN PRESS, pages: 1743 - 1764 |
C. HAY: "Enhanced expression of a furin-cleavable proinsulin", JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol. 31, no. 3, 1 December 2003 (2003-12-01), pages 597 - 607, XP055011942, ISSN: 0952-5041, DOI: 10.1677/jme.0.0310597 * |
CARTER, CURRENT OPINIONS IN BIOTECHNOLOGY, 1992, pages 1533 - 539 |
CLARK ET AL., GENE THERAPY, vol. 3, 1996, pages 1124 - 1132 |
CLARK ET AL., HUM. GENE THER., vol. 10, no. 6, 1999, pages 1031 - 1039 |
CSEIJESIOLSON, MOL CELL BIOL, vol. 11, 1991, pages 4854 - 4862 |
DATABASE Geneseq [online] 9 August 2018 (2018-08-09), "Apolipoprotein B-100 signal peptide, SEQ ID 78.", XP002810496, retrieved from EBI accession no. GSP:BFJ45512 Database accession no. BFJ45512 * |
DUCKERT ET AL., PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 17, no. 1, 2004, pages 107 - 112 |
GROSKREUTZ D J ET AL: "GENETICALLY ENGINEERED PROINSULIN CONSTITUTIVELY PROCESSED AND SECRETED AS MATURE, ACTIVE INSULIN", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 269, no. 8, 25 February 1994 (1994-02-25), pages 6241 - 6245, XP000616534, ISSN: 0021-9258 * |
HERMONAT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6466 |
JOHNSON ET AL., MOL CELL BIOL, vol. 9, 1989, pages 3393 - 3399 |
KON OI LIAN ET AL: "Naked plasmid-mediated gene transfer to skeletal muscle ameliorates diabetes mellitus", THE JOURNAL OF GENE MEDICINE, vol. 1, no. 3, 1 May 1999 (1999-05-01), US, pages 186 - 194, XP093100950, ISSN: 1099-498X, DOI: 10.1002/(SICI)1521-2254(199905/06)1:3<186::AID-JGM33>3.0.CO;2-W * |
LAUGHLIN ET AL., GENE, vol. 23, 1983, pages 65 - 73 |
LEBKOWSKI ET AL., MOL. CELL. BIOL., vol. 7, 1988, pages 349 |
LI ET AL., NAT. BIOTECHNOL., vol. 17, no. 3, 1999, pages 241 - 245 |
LIU ET AL., PLASMID, vol. 106, 2019, pages 102441 |
MADERWHITE, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5603 - 5607 |
MARSIC ET AL., MOLECULAR THERAPY, vol. 22, no. 11, 2014, pages 1900 - 1909 |
MARTINENGHI S ET AL: "Human insulin production and amelioration of diabetes in mice by electrotransfer-enhanced plasmid DNA gene transfer to the skeletal muscle", GENE THERAPY, NATURE PUBLISHING GROUP, LONDON, GB, vol. 9, no. 21, 14 October 2002 (2002-10-14), pages 1429 - 1437, XP037770575, ISSN: 0969-7128, [retrieved on 20021014], DOI: 10.1038/SJ.GT.3301804 * |
MCLAUGHLIN ET AL., J. VIROL., vol. 62, 1988, pages 1963 - 174 |
MUSCAT ET AL., MOL CELL BIOL, vol. 7, 1987, pages 4089 - 4099 |
MUZYCZKA, CURR. TOPICS IN MICROBIAL, AND IMMUNOL., vol. 158, 1992, pages 97 - 129 |
NISHIGORI T ET AL: "Proinsulin cleaved by furin is processed to chromatographically mature insulin by carboxypeptidases in nonneuroendocrine cells", PEPTIDES, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 5, 1 January 1996 (1996-01-01), pages 789 - 796, XP002524490, ISSN: 0196-9781, DOI: 10.1016/0196-9781(96)00077-0 * |
PAUL ET AL., HUMAN GENE THERAPY, vol. 4, 1993, pages 609 - 615 |
PERRIN ET AL., VACCINE, vol. 13, 1995, pages 1244 - 1250 |
RATSCHIN ET AL., MOL. CELL. BIOL., vol. 4, 1984, pages 2072 |
RICHARD J BARTLETT ET AL: "Adeno-associated virus based gene therapy in skeletal muscle", GENE TARGETING PROTOCOLS / ED. BY ERIC KMIEC; [METHODS IN MOLECULAR BIOLOGY, VOLUME 133 - ISSN 1064-3745], TOTOWA, NJ : HUMANA PRESS, C 2000, US, 1 January 2000 (2000-01-01), pages 127 - 156, XP008165658, ISBN: 978-0-89603-360-3, DOI: 10.1385/1-59259-215-5:127 * |
ROSE: "Comprehensive Virology", vol. 3, 1974, pages: 1 - 61 |
SAMULSKI ET AL., J. VIROL., vol. 63, 1989, pages 3822 - 3828 |
SAMULSKI ET AL., PROC. NATL. ACAD. S6. USA, vol. 79, 1982, pages 2077 - 2081 |
SCHENPPCLARK, METHODS MOL. MED., 2002, pages 69427 - 443 |
SEMENZA ET AL., PROC NATL ACAD SCI USA, vol. 88, 1991, pages 5680 - 5684 |
SENAPATHYCARTER, J. BIOL. CHEM, vol. 259, 1983, pages 4661 - 4666 |
SKOPENKOVA ET AL.: "Muscle-Specific Promoters for Gene Therapy", ACTA NATURAE, vol. 13, no. 1, 2021, pages 47 - 58 |
TIAN ET AL., SCIENTIFIC REPORTS, vol. 2, 2012, pages 261 |
TRATSCHIN ET AL., MOL. CELL. BIOL., vol. 5, 1985, pages 3251 |
WEINTRAUB ET AL., SCIENCE, vol. 251, 1991, pages 761 - 766 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230173101A1 (en) | Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy | |
EP3596222B1 (en) | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy | |
US20210260218A1 (en) | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy | |
US20230049491A1 (en) | Adeno-Associated Virus Vector Delivery of a Fragment of Micro-Dystrophin to Treat Muscular Dystrophy | |
US20230302157A1 (en) | Adeno-Associated Virus Vector Delivery of Muscle Specific Micro-Dystrophin to Treat Muscular Dystrophy | |
CN114072514A (en) | Compositions and methods for treating ATPase mediated diseases | |
WO2024035782A1 (en) | Aav-mediated intramuscular delivery of insulin | |
EP4198134A1 (en) | Gamma-sarcoglycan gene transfer increase using modified itr sequences | |
US20230136699A1 (en) | Gene therapy for maple syrup urine disease | |
EP4198046A1 (en) | Alpha-sarcoglycan gene transfer increase using modified itr sequences | |
CA3104471A1 (en) | Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies | |
WO2024050064A1 (en) | Hybrid aav capsid and uses thereof | |
TW202328446A (en) | Treatment of muscular dystrophy | |
CN116179605A (en) | Recombinant adeno-associated virus vector and application thereof | |
EA042315B1 (en) | DELIVERY OF MICRODYSTROFIN WITH A VECTOR BASED ON ADENO-ASSOCIATED VIRUS FOR THE TREATMENT OF MUSCULAR DYSTROPHY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23764761 Country of ref document: EP Kind code of ref document: A1 |